<?xml version="1.0" encoding="utf-8"?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1987-08-13" modified="2020-10-07" version="270">
<accession>P05106</accession>
<accession>A0PJW2</accession>
<accession>D3DXJ8</accession>
<accession>O15495</accession>
<accession>Q12806</accession>
<accession>Q13413</accession>
<accession>Q14648</accession>
<accession>Q16499</accession>
<name>ITB3_HUMAN</name>
<protein>
<recommendedName>
<fullName evidence="98">Integrin beta-3</fullName>
</recommendedName>
<alternativeName>
<fullName evidence="98">Platelet membrane glycoprotein IIIa</fullName>
<shortName evidence="98">GPIIIa</shortName>
</alternativeName>
<cdAntigenName>CD61</cdAntigenName>
</protein>
<gene>
<name type="primary" evidence="100">ITGB3</name>
<name type="synonym">GP3A</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1987" name="J. Biol. Chem." volume="262" first="3936" last="3939">
<title>Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone. Identity with platelet glycoprotein IIIa and similarity to 'integrin'.</title>
<authorList>
<person name="Fitzgerald L.A."/>
<person name="Steiner B."/>
<person name="Rall S.C. Jr."/>
<person name="Lo S."/>
<person name="Phillips D.R."/>
</authorList>
<dbReference type="PubMed" id="3494014"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-3A)</scope>
</reference>
<reference key="2">
<citation type="journal article" date="1988" name="J. Clin. Invest." volume="81" first="1470" last="1475">
<title>Structure of platelet glycoprotein IIIa. A common subunit for two different membrane receptors.</title>
<authorList>
<person name="Zimrin A.B."/>
<person name="Eisman R."/>
<person name="Vilaire G."/>
<person name="Schwartz E."/>
<person name="Bennett J.S."/>
<person name="Poncz M."/>
</authorList>
<dbReference type="PubMed" id="2452834"/>
<dbReference type="DOI" id="10.1172/jci113478"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-3A)</scope>
</reference>
<reference key="3">
<citation type="journal article" date="1990" name="Mol. Biol. Rep." volume="14" first="27" last="33">
<title>GPIIb and GPIIIa amino acid sequences deduced from human megakaryocyte cDNAs.</title>
<authorList>
<person name="Frachet P."/>
<person name="Uzan G."/>
<person name="Thevenon D."/>
<person name="Denarier E."/>
<person name="Prandini M.H."/>
<person name="Marguerie G."/>
</authorList>
<dbReference type="PubMed" id="2345548"/>
<dbReference type="DOI" id="10.1007/bf00422712"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-3A)</scope>
</reference>
<reference key="4">
<citation type="journal article" date="1997" name="J. Biol. Chem." volume="272" first="16390" last="16397">
<title>Cloning and characterization of a novel integrin beta3 subunit.</title>
<authorList>
<person name="Kumar C.S."/>
<person name="James I.E."/>
<person name="Wong A."/>
<person name="Mwangi V."/>
<person name="Feild J.A."/>
<person name="Nuthulaganti P."/>
<person name="Connor J.R."/>
<person name="Eichman C."/>
<person name="Ali F."/>
<person name="Hwang S.M."/>
<person name="Rieman D.J."/>
<person name="Drake F.H."/>
<person name="Gowen M."/>
</authorList>
<dbReference type="PubMed" id="9195946"/>
<dbReference type="DOI" id="10.1074/jbc.272.26.16390"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-3C)</scope>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<source>
<tissue>Osteoclastoma</tissue>
</source>
</reference>
<reference key="5">
<citation type="submission" date="2005-09" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Mural R.J."/>
<person name="Istrail S."/>
<person name="Sutton G.G."/>
<person name="Florea L."/>
<person name="Halpern A.L."/>
<person name="Mobarry C.M."/>
<person name="Lippert R."/>
<person name="Walenz B."/>
<person name="Shatkay H."/>
<person name="Dew I."/>
<person name="Miller J.R."/>
<person name="Flanigan M.J."/>
<person name="Edwards N.J."/>
<person name="Bolanos R."/>
<person name="Fasulo D."/>
<person name="Halldorsson B.V."/>
<person name="Hannenhalli S."/>
<person name="Turner R."/>
<person name="Yooseph S."/>
<person name="Lu F."/>
<person name="Nusskern D.R."/>
<person name="Shue B.C."/>
<person name="Zheng X.H."/>
<person name="Zhong F."/>
<person name="Delcher A.L."/>
<person name="Huson D.H."/>
<person name="Kravitz S.A."/>
<person name="Mouchard L."/>
<person name="Reinert K."/>
<person name="Remington K.A."/>
<person name="Clark A.G."/>
<person name="Waterman M.S."/>
<person name="Eichler E.E."/>
<person name="Adams M.D."/>
<person name="Hunkapiller M.W."/>
<person name="Myers E.W."/>
<person name="Venter J.C."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="6">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BETA-3A)</scope>
</reference>
<reference key="7">
<citation type="journal article" date="1994" name="Blood" volume="83" first="668" last="676">
<title>Isolation and characterization of a TATA-less promoter for the human beta 3 integrin gene.</title>
<authorList>
<person name="Villa-Garcia M."/>
<person name="Li L."/>
<person name="Riely G."/>
<person name="Bray P.F."/>
</authorList>
<dbReference type="PubMed" id="8298129"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-26</scope>
<source>
<tissue>Blood</tissue>
</source>
</reference>
<reference key="8">
<citation type="journal article" date="1988" name="Blood" volume="72" first="593" last="600">
<title>Cloning of glycoprotein IIIa cDNA from human erythroleukemia cells and localization of the gene to chromosome 17.</title>
<authorList>
<person name="Rosa J.P."/>
<person name="Bray P.F."/>
<person name="Gayet O."/>
<person name="Johnston G.I."/>
<person name="Cook R.G."/>
<person name="Jackson K.W."/>
<person name="Shuman M.A."/>
<person name="McEver R.P."/>
</authorList>
<dbReference type="PubMed" id="3165296"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 11-788</scope>
<source>
<tissue>Erythroleukemia</tissue>
</source>
</reference>
<reference key="9">
<citation type="journal article" date="1991" name="Biochem. J." volume="279" first="419" last="425">
<title>Separation of important new platelet glycoproteins (GPIa, GPIc, GPIc*, GPIIa and GMP-140) by F.P.L.C. Characterization by monoclonal antibodies and gas-phase sequencing.</title>
<authorList>
<person name="Catimel B."/>
<person name="Parmentier S."/>
<person name="Leung L.L."/>
<person name="McGregor J.L."/>
</authorList>
<dbReference type="PubMed" id="1953640"/>
<dbReference type="DOI" id="10.1042/bj2790419"/>
</citation>
<scope>PROTEIN SEQUENCE OF 27-37</scope>
<source>
<tissue>Platelet</tissue>
</source>
</reference>
<reference key="10">
<citation type="journal article" date="2003" name="Nat. Biotechnol." volume="21" first="566" last="569">
<title>Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.</title>
<authorList>
<person name="Gevaert K."/>
<person name="Goethals M."/>
<person name="Martens L."/>
<person name="Van Damme J."/>
<person name="Staes A."/>
<person name="Thomas G.R."/>
<person name="Vandekerckhove J."/>
</authorList>
<dbReference type="PubMed" id="12665801"/>
<dbReference type="DOI" id="10.1038/nbt810"/>
</citation>
<scope>PROTEIN SEQUENCE OF 27-34</scope>
<source>
<tissue>Platelet</tissue>
</source>
</reference>
<reference key="11">
<citation type="journal article" date="1990" name="J. Biol. Chem." volume="265" first="8590" last="8595">
<title>The genomic organization of platelet glycoprotein IIIa.</title>
<authorList>
<person name="Zimrin A.B."/>
<person name="Gidwitz S."/>
<person name="Lord S."/>
<person name="Schwartz E."/>
<person name="Bennett J.S."/>
<person name="White G.C. II"/>
<person name="Poncz M."/>
</authorList>
<dbReference type="PubMed" id="2341395"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 28-788</scope>
</reference>
<reference key="12">
<citation type="journal article" date="1990" name="J. Biol. Chem." volume="265" first="18098" last="18103">
<title>Characterization of the human platelet glycoprotein IIIa gene. Comparison with the fibronectin receptor beta-subunit gene.</title>
<authorList>
<person name="Lanza F."/>
<person name="Kieffer N."/>
<person name="Phillips D.R."/>
<person name="Fitzgerald L.A."/>
</authorList>
<dbReference type="PubMed" id="2145280"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 28-788</scope>
</reference>
<reference key="13">
<citation type="submission" date="1993-12" db="EMBL/GenBank/DDBJ databases">
<title>A new exon II polymorphism in the platelet glycoprotein IIIa.</title>
<authorList>
<person name="Pascual C."/>
<person name="Balas A."/>
<person name="Garcia-Sanchez F."/>
<person name="Rodriguez de la Rua A."/>
<person name="Vicario J.L."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 56-120</scope>
<scope>VARIANTS PRO-59 AND ARG-66</scope>
<source>
<tissue>Blood</tissue>
</source>
</reference>
<reference key="14">
<citation type="journal article" date="1992" name="Int. Immunol." volume="4" first="1031" last="1040">
<title>The gene organization of the human beta 7 subunit, the common beta subunit of the leukocyte integrins HML-1 and LPAM-1.</title>
<authorList>
<person name="Jiang W.-M."/>
<person name="Jenkins D."/>
<person name="Yuan Q."/>
<person name="Leung E."/>
<person name="Choo K.H."/>
<person name="Watson J.D."/>
<person name="Krissansen G.W."/>
</authorList>
<dbReference type="PubMed" id="1382574"/>
<dbReference type="DOI" id="10.1093/intimm/4.9.1031"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 122-204</scope>
</reference>
<reference key="15">
<citation type="journal article" date="1987" name="Blood" volume="69" first="560" last="564">
<title>Purification and partial amino acid sequence of human platelet membrane glycoproteins IIb and IIIa.</title>
<authorList>
<person name="Hiraiwa A."/>
<person name="Matsukage A."/>
<person name="Shiku H."/>
<person name="Takahashi T."/>
<person name="Naito K."/>
<person name="Yamada K."/>
</authorList>
<dbReference type="PubMed" id="3801670"/>
</citation>
<scope>PROTEIN SEQUENCE OF 218-234 AND 439-443</scope>
</reference>
<reference key="16">
<citation type="journal article" date="1989" name="Proc. Natl. Acad. Sci. U.S.A." volume="86" first="5415" last="5418">
<title>An alternative cytoplasmic domain of the integrin beta 3 subunit.</title>
<authorList>
<person name="Van Kuppevelt T.H.M.S.M."/>
<person name="Languino L.R."/>
<person name="Gailit J.O."/>
<person name="Suzuki S."/>
<person name="Ruoslahti E."/>
</authorList>
<dbReference type="PubMed" id="2787511"/>
<dbReference type="DOI" id="10.1073/pnas.86.14.5415"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 707-788 (ISOFORM BETA-3B)</scope>
<source>
<tissue>Placenta</tissue>
</source>
</reference>
<reference key="17">
<citation type="journal article" date="1991" name="Biochem. J." volume="274" first="63" last="71">
<title>Assignment of disulphide bonds in human platelet GPIIIa. A disulphide pattern for the beta-subunits of the integrin family.</title>
<authorList>
<person name="Calvete J.J."/>
<person name="Henschen A."/>
<person name="Gonzalez-Rodriguez J."/>
</authorList>
<dbReference type="PubMed" id="2001252"/>
<dbReference type="DOI" id="10.1042/bj2740063"/>
</citation>
<scope>PARTIAL PROTEIN SEQUENCE</scope>
<scope>DISULFIDE BONDS</scope>
</reference>
<reference key="18">
<citation type="journal article" date="1994" name="Virology" volume="203" first="357" last="365">
<title>Entry of coxsackievirus A9 into host cells: specific interactions with alpha v beta 3 integrin, the vitronectin receptor.</title>
<authorList>
<person name="Roivainen M."/>
<person name="Piirainen L."/>
<person name="Hovi T."/>
<person name="Virtanen I."/>
<person name="Riikonen T."/>
<person name="Heino J."/>
<person name="Hyypiae T."/>
</authorList>
<dbReference type="PubMed" id="7519807"/>
<dbReference type="DOI" id="10.1006/viro.1994.1494"/>
</citation>
<scope>FUNCTION (MICROBIAL INFECTION)</scope>
<scope>INTERACTION WITH COXSACKIEVIRUS A9 CAPSID PROTEINS</scope>
</reference>
<reference key="19">
<citation type="journal article" date="1996" name="J. Biol. Chem." volume="271" first="10811" last="10815">
<title>Outside-in integrin signal transduction. Alpha IIb beta 3-(GP IIb IIIa) tyrosine phosphorylation induced by platelet aggregation.</title>
<authorList>
<person name="Law D.A."/>
<person name="Nannizzi-Alaimo L."/>
<person name="Phillips D.R."/>
</authorList>
<dbReference type="PubMed" id="8631894"/>
<dbReference type="DOI" id="10.1074/jbc.271.18.10811"/>
</citation>
<scope>PHOSPHORYLATION AT TYR-773 AND TYR-785 (ISOFORM BETA-3A)</scope>
</reference>
<reference key="20">
<citation type="journal article" date="1998" name="Proc. Natl. Acad. Sci. U.S.A." volume="95" first="7074" last="7079">
<title>beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure.</title>
<authorList>
<person name="Gavrilovskaya I.N."/>
<person name="Shepley M."/>
<person name="Shaw R."/>
<person name="Ginsberg M.H."/>
<person name="Mackow E.R."/>
</authorList>
<dbReference type="PubMed" id="9618541"/>
<dbReference type="DOI" id="10.1073/pnas.95.12.7074"/>
</citation>
<scope>FUNCTION (MICROBIAL INFECTION)</scope>
<scope>INTERACTION WITH HANTAAN GLYCOPROTEIN G</scope>
</reference>
<reference key="21">
<citation type="journal article" date="1999" name="Blood" volume="94" first="663" last="672">
<title>The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor.</title>
<authorList>
<person name="Barillari G."/>
<person name="Sgadari C."/>
<person name="Fiorelli V."/>
<person name="Samaniego F."/>
<person name="Colombini S."/>
<person name="Manzari V."/>
<person name="Modesti A."/>
<person name="Nair B.C."/>
<person name="Cafaro A."/>
<person name="Stuerzl M."/>
<person name="Ensoli B."/>
</authorList>
<dbReference type="PubMed" id="10397733"/>
</citation>
<scope>FUNCTION (MICROBIAL INFECTION)</scope>
<scope>INTERACTION WITH HIV-1 TAT</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2000" name="J. Biol. Chem." volume="275" first="30901" last="30906">
<title>Threonine phosphorylation of the beta 3 integrin cytoplasmic tail, at a site recognized by PDK1 and Akt/PKB in vitro, regulates Shc binding.</title>
<authorList>
<person name="Kirk R.I."/>
<person name="Sanderson M.R."/>
<person name="Lerea K.M."/>
</authorList>
<dbReference type="PubMed" id="10896934"/>
<dbReference type="DOI" id="10.1074/jbc.m001908200"/>
</citation>
<scope>PHOSPHORYLATION AT THR-779</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2001" name="J. Virol." volume="75" first="1958" last="1967">
<title>Entry of human parechovirus 1.</title>
<authorList>
<person name="Joki-Korpela P."/>
<person name="Marjomaki V."/>
<person name="Krogerus C."/>
<person name="Heino J."/>
<person name="Hyypia T."/>
</authorList>
<dbReference type="PubMed" id="11160695"/>
<dbReference type="DOI" id="10.1128/jvi.75.4.1958-1967.2001"/>
</citation>
<scope>FUNCTION (MICROBIAL INFECTION)</scope>
<scope>INTERACTION WITH HUMAN PARECHOVIRUS 1 CAPSID PROTEINS</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2002" name="J. Cell Biol." volume="157" first="265" last="275">
<title>Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton.</title>
<authorList>
<person name="Obergfell A."/>
<person name="Eto K."/>
<person name="Mocsai A."/>
<person name="Buensuceso C."/>
<person name="Moores S.L."/>
<person name="Brugge J.S."/>
<person name="Lowell C.A."/>
<person name="Shattil S.J."/>
</authorList>
<dbReference type="PubMed" id="11940607"/>
<dbReference type="DOI" id="10.1083/jcb.200112113"/>
</citation>
<scope>INTERACTION WITH SYK</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2002" name="J. Cell Biol." volume="156" first="361" last="376">
<title>Different splice variants of filamin-B affect myogenesis, subcellular distribution, and determine binding to integrin (beta) subunits.</title>
<authorList>
<person name="van Der Flier A."/>
<person name="Kuikman I."/>
<person name="Kramer D."/>
<person name="Geerts D."/>
<person name="Kreft M."/>
<person name="Takafuta T."/>
<person name="Shapiro S.S."/>
<person name="Sonnenberg A."/>
</authorList>
<dbReference type="PubMed" id="11807098"/>
<dbReference type="DOI" id="10.1083/jcb.200103037"/>
</citation>
<scope>INTERACTION WITH FLNB</scope>
<source>
<tissue>Keratinocyte</tissue>
<tissue>Skeletal muscle</tissue>
</source>
</reference>
<reference key="26">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="24200" last="24208">
<title>CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family.</title>
<authorList>
<person name="Lin C.G."/>
<person name="Leu S.J."/>
<person name="Chen N."/>
<person name="Tebeau C.M."/>
<person name="Lin S.X."/>
<person name="Yeung C.Y."/>
<person name="Lau L.F."/>
</authorList>
<dbReference type="PubMed" id="12695522"/>
<dbReference type="DOI" id="10.1074/jbc.m302028200"/>
</citation>
<scope>INTERACTION WITH CCN3</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="34605" last="34616">
<title>Cell adhesion to fibrillin-1 molecules and microfibrils is mediated by alpha 5 beta 1 and alpha v beta 3 integrins.</title>
<authorList>
<person name="Bax D.V."/>
<person name="Bernard S.E."/>
<person name="Lomas A."/>
<person name="Morgan A."/>
<person name="Humphries J."/>
<person name="Shuttleworth C.A."/>
<person name="Humphries M.J."/>
<person name="Kielty C.M."/>
</authorList>
<dbReference type="PubMed" id="12807887"/>
<dbReference type="DOI" id="10.1074/jbc.m303159200"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH FBN1</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2004" name="Nat. Cell Biol." volume="6" first="523" last="531">
<title>Myosin-X provides a motor-based link between integrins and the cytoskeleton.</title>
<authorList>
<person name="Zhang H."/>
<person name="Berg J.S."/>
<person name="Li Z."/>
<person name="Wang Y."/>
<person name="Lang P."/>
<person name="Sousa A.D."/>
<person name="Bhaskar A."/>
<person name="Cheney R.E."/>
<person name="Stromblad S."/>
</authorList>
<dbReference type="PubMed" id="15156152"/>
<dbReference type="DOI" id="10.1038/ncb1136"/>
</citation>
<scope>INTERACTION WITH MYO10</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2005" name="Nat. Med." volume="11" first="515" last="521">
<title>Integrin alphavbeta3 is a coreceptor for human cytomegalovirus.</title>
<authorList>
<person name="Wang X."/>
<person name="Huang D.Y."/>
<person name="Huong S.M."/>
<person name="Huang E.S."/>
</authorList>
<dbReference type="PubMed" id="15834425"/>
<dbReference type="DOI" id="10.1038/nm1236"/>
</citation>
<scope>FUNCTION (MICROBIAL INFECTION)</scope>
<scope>INTERACTION WITH CYTOMEGALOVIRUS/HHV-5 GH:GL PROTEINS</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2005" name="Blood" volume="105" first="1500" last="1507">
<title>A role for the thiol isomerase protein ERP5 in platelet function.</title>
<authorList>
<person name="Jordan P.A."/>
<person name="Stevens J.M."/>
<person name="Hubbard G.P."/>
<person name="Barrett N.E."/>
<person name="Sage T."/>
<person name="Authi K.S."/>
<person name="Gibbins J.M."/>
</authorList>
<dbReference type="PubMed" id="15466936"/>
<dbReference type="DOI" id="10.1182/blood-2004-02-0608"/>
</citation>
<scope>INTERACTION WITH PDIA6</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2005" name="Dev. Biol." volume="287" first="336" last="345">
<title>Epithelial membrane protein-2 regulates surface expression of alphavbeta3 integrin in the endometrium.</title>
<authorList>
<person name="Wadehra M."/>
<person name="Forbes A."/>
<person name="Pushkarna N."/>
<person name="Goodglick L."/>
<person name="Gordon L.K."/>
<person name="Williams C.J."/>
<person name="Braun J."/>
</authorList>
<dbReference type="PubMed" id="16216233"/>
<dbReference type="DOI" id="10.1016/j.ydbio.2005.09.003"/>
</citation>
<scope>INTERACTION WITH EMP2</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2005" name="J. Biol. Chem." volume="280" first="32655" last="32661">
<title>Cartilage oligomeric matrix protein/thrombospondin 5 supports chondrocyte attachment through interaction with integrins.</title>
<authorList>
<person name="Chen F.-H."/>
<person name="Thomas A.O."/>
<person name="Hecht J.T."/>
<person name="Goldring M.B."/>
<person name="Lawler J."/>
</authorList>
<dbReference type="PubMed" id="16051604"/>
<dbReference type="DOI" id="10.1074/jbc.m504778200"/>
</citation>
<scope>INTERACTION WITH COMP</scope>
</reference>
<reference key="33">
<citation type="journal article" date="2005" name="J. Clin. Invest." volume="115" first="3363" last="3369">
<title>Structure and function of the platelet integrin alphaIIbbeta3.</title>
<authorList>
<person name="Bennett J.S."/>
</authorList>
<dbReference type="PubMed" id="16322781"/>
<dbReference type="DOI" id="10.1172/jci26989"/>
</citation>
<scope>REVIEW</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2005" name="J. Proteome Res." volume="4" first="2070" last="2080">
<title>Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.</title>
<authorList>
<person name="Liu T."/>
<person name="Qian W.-J."/>
<person name="Gritsenko M.A."/>
<person name="Camp D.G. II"/>
<person name="Monroe M.E."/>
<person name="Moore R.J."/>
<person name="Smith R.D."/>
</authorList>
<dbReference type="PubMed" id="16335952"/>
<dbReference type="DOI" id="10.1021/pr0502065"/>
</citation>
<scope>GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-125</scope>
<source>
<tissue>Plasma</tissue>
</source>
</reference>
<reference key="35">
<citation type="journal article" date="2006" name="J. Biol. Chem." volume="281" first="34179" last="34188">
<title>Proteolytically processed soluble tumor endothelial marker (TEM) 5 mediates endothelial cell survival during angiogenesis by linking integrin alpha(v)beta3 to glycosaminoglycans.</title>
<authorList>
<person name="Vallon M."/>
<person name="Essler M."/>
</authorList>
<dbReference type="PubMed" id="16982628"/>
<dbReference type="DOI" id="10.1074/jbc.m605291200"/>
</citation>
<scope>INTERACTION WITH ADGRA2</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2006" name="Mol. Cell. Proteomics" volume="5" first="226" last="233">
<title>Elucidation of N-glycosylation sites on human platelet proteins: a glycoproteomic approach.</title>
<authorList>
<person name="Lewandrowski U."/>
<person name="Moebius J."/>
<person name="Walter U."/>
<person name="Sickmann A."/>
</authorList>
<dbReference type="PubMed" id="16263699"/>
<dbReference type="DOI" id="10.1074/mcp.m500324-mcp200"/>
</citation>
<scope>GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-125</scope>
<source>
<tissue>Platelet</tissue>
</source>
</reference>
<reference key="37">
<citation type="journal article" date="2007" name="J. Thromb. Haemost." volume="5" first="1345" last="1352">
<title>Platelet integrin alpha(IIb)beta(3): activation mechanisms.</title>
<authorList>
<person name="Ma Y.Q."/>
<person name="Qin J."/>
<person name="Plow E.F."/>
</authorList>
<dbReference type="PubMed" id="17635696"/>
<dbReference type="DOI" id="10.1111/j.1538-7836.2007.02537.x"/>
</citation>
<scope>REVIEW</scope>
</reference>
<reference key="38">
<citation type="journal article" date="2008" name="J. Biol. Chem." volume="283" first="18066" last="18075">
<title>Direct binding of integrin alphavbeta3 to FGF1 plays a role in FGF1 signaling.</title>
<authorList>
<person name="Mori S."/>
<person name="Wu C.Y."/>
<person name="Yamaji S."/>
<person name="Saegusa J."/>
<person name="Shi B."/>
<person name="Ma Z."/>
<person name="Kuwabara Y."/>
<person name="Lam K.S."/>
<person name="Isseroff R.R."/>
<person name="Takada Y.K."/>
<person name="Takada Y."/>
</authorList>
<dbReference type="PubMed" id="18441324"/>
<dbReference type="DOI" id="10.1074/jbc.m801213200"/>
</citation>
<scope>FUNCTION</scope>
<scope>BINDING TO FGF1</scope>
<scope>IDENTIFICATION IN A COMPLEX WITH FGF1 AND FGFR1</scope>
</reference>
<reference key="39">
<citation type="journal article" date="2008" name="J. Biol. Chem." volume="283" first="26107" last="26115">
<title>Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins alphavbeta3 and alpha4beta1 and induces proliferation of monocytic cells in an integrin-dependent manner.</title>
<authorList>
<person name="Saegusa J."/>
<person name="Akakura N."/>
<person name="Wu C.Y."/>
<person name="Hoogland C."/>
<person name="Ma Z."/>
<person name="Lam K.S."/>
<person name="Liu F.T."/>
<person name="Takada Y.K."/>
<person name="Takada Y."/>
</authorList>
<dbReference type="PubMed" id="18635536"/>
<dbReference type="DOI" id="10.1074/jbc.m804835200"/>
</citation>
<scope>FUNCTION</scope>
</reference>
<reference key="40">
<citation type="journal article" date="2008" name="J. Proteome Res." volume="7" first="526" last="534">
<title>Phosphoproteome of resting human platelets.</title>
<authorList>
<person name="Zahedi R.P."/>
<person name="Lewandrowski U."/>
<person name="Wiesner J."/>
<person name="Wortelkamp S."/>
<person name="Moebius J."/>
<person name="Schuetz C."/>
<person name="Walter U."/>
<person name="Gambaryan S."/>
<person name="Sickmann A."/>
</authorList>
<dbReference type="PubMed" id="18088087"/>
<dbReference type="DOI" id="10.1021/pr0704130"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-773</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Platelet</tissue>
</source>
</reference>
<reference key="41">
<citation type="journal article" date="2008" name="J. Virol." volume="82" first="1570" last="1580">
<title>Integrin alphaVbeta3 Binds to the RGD motif of glycoprotein B of Kaposi's sarcoma-associated herpesvirus and functions as an RGD-dependent entry receptor.</title>
<authorList>
<person name="Garrigues H.J."/>
<person name="Rubinchikova Y.E."/>
<person name="Dipersio C.M."/>
<person name="Rose T.M."/>
</authorList>
<dbReference type="PubMed" id="18045938"/>
<dbReference type="DOI" id="10.1128/jvi.01673-07"/>
</citation>
<scope>FUNCTION (MICROBIAL INFECTION)</scope>
<scope>INTERACTION WITH HHV-8 GLYCOPROTEIN B</scope>
</reference>
<reference key="42">
<citation type="journal article" date="2009" name="Blood" volume="114" first="1954" last="1957">
<title>Naturally processed peptides spanning the HPA-1a polymorphism are efficiently generated and displayed from platelet glycoprotein by HLA-DRB3*0101-positive antigen-presenting cells.</title>
<authorList>
<person name="Anani Sarab G."/>
<person name="Moss M."/>
<person name="Barker R.N."/>
<person name="Urbaniak S.J."/>
</authorList>
<dbReference type="PubMed" id="19494351"/>
<dbReference type="DOI" id="10.1182/blood-2009-04-211839"/>
</citation>
<scope>IDENTIFICATION OF ALLOANTIGEN HPA-1A BY MASS SPECTROMETRY</scope>
<scope>ASSOCIATION TO ALLELE HLA-DRB3*01:01</scope>
</reference>
<reference key="43">
<citation type="journal article" date="2009" name="FASEB J." volume="23" first="1459" last="1469">
<title>Integrin alpha(v)beta(3) is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase beta/zeta.</title>
<authorList>
<person name="Mikelis C."/>
<person name="Sfaelou E."/>
<person name="Koutsioumpa M."/>
<person name="Kieffer N."/>
<person name="Papadimitriou E."/>
</authorList>
<dbReference type="PubMed" id="19141530"/>
<dbReference type="DOI" id="10.1096/fj.08-117564"/>
</citation>
<scope>INTERACTION WITH PTN</scope>
<scope>PHOSPHORYLATION AT TYR-773</scope>
</reference>
<reference key="44">
<citation type="journal article" date="2009" name="J. Biol. Chem." volume="284" first="24106" last="24114">
<title>The direct binding of insulin-like growth factor-1 (IGF-1) to integrin alphavbeta3 is involved in IGF-1 signaling.</title>
<authorList>
<person name="Saegusa J."/>
<person name="Yamaji S."/>
<person name="Ieguchi K."/>
<person name="Wu C.Y."/>
<person name="Lam K.S."/>
<person name="Liu F.T."/>
<person name="Takada Y.K."/>
<person name="Takada Y."/>
</authorList>
<dbReference type="PubMed" id="19578119"/>
<dbReference type="DOI" id="10.1074/jbc.m109.013201"/>
</citation>
<scope>FUNCTION</scope>
<scope>BINDING TO IGF1</scope>
<scope>IDENTIFICATION IN A COMPLEX WITH IGF1 AND IGF1R</scope>
</reference>
<reference key="45">
<citation type="journal article" date="2009" name="J. Proteome Res." volume="8" first="651" last="661">
<title>Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry.</title>
<authorList>
<person name="Chen R."/>
<person name="Jiang X."/>
<person name="Sun D."/>
<person name="Han G."/>
<person name="Wang F."/>
<person name="Ye M."/>
<person name="Wang L."/>
<person name="Zou H."/>
</authorList>
<dbReference type="PubMed" id="19159218"/>
<dbReference type="DOI" id="10.1021/pr8008012"/>
</citation>
<scope>GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-680</scope>
<source>
<tissue>Liver</tissue>
</source>
</reference>
<reference key="46">
<citation type="journal article" date="2010" name="J. Biol. Chem." volume="285" first="30370" last="30374">
<title>Tyrosine phosphorylation of integrin beta3 regulates kindlin-2 binding and integrin activation.</title>
<authorList>
<person name="Bledzka K."/>
<person name="Bialkowska K."/>
<person name="Nie H."/>
<person name="Qin J."/>
<person name="Byzova T."/>
<person name="Wu C."/>
<person name="Plow E.F."/>
<person name="Ma Y.Q."/>
</authorList>
<dbReference type="PubMed" id="20702409"/>
<dbReference type="DOI" id="10.1074/jbc.c110.134247"/>
</citation>
<scope>INTERACTION WITH FERMT2</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="47">
<citation type="journal article" date="2010" name="J. Biol. Chem." volume="285" first="31388" last="31398">
<title>Direct binding of the EGF-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signaling.</title>
<authorList>
<person name="Ieguchi K."/>
<person name="Fujita M."/>
<person name="Ma Z."/>
<person name="Davari P."/>
<person name="Taniguchi Y."/>
<person name="Sekiguchi K."/>
<person name="Wang B."/>
<person name="Takada Y.K."/>
<person name="Takada Y."/>
</authorList>
<dbReference type="PubMed" id="20682778"/>
<dbReference type="DOI" id="10.1074/jbc.m110.113878"/>
</citation>
<scope>FUNCTION</scope>
<scope>BINDING TO NRG1</scope>
<scope>IDENTIFICATION IN A COMPLEX WITH NRG1 AND ERBB3</scope>
</reference>
<reference key="48">
<citation type="journal article" date="2012" name="J. Bone Miner. Res." volume="27" first="2024" last="2034">
<title>DICAM inhibits osteoclast differentiation through attenuation of the integrin alphaVbeta3 pathway.</title>
<authorList>
<person name="Jung Y.K."/>
<person name="Han S.W."/>
<person name="Kim G.W."/>
<person name="Jeong J.H."/>
<person name="Kim H.J."/>
<person name="Choi J.Y."/>
</authorList>
<dbReference type="PubMed" id="22492581"/>
<dbReference type="DOI" id="10.1002/jbmr.1632"/>
</citation>
<scope>INTERACTION WITH MXRA8</scope>
</reference>
<reference key="49">
<citation type="journal article" date="2012" name="J. Immunol." volume="189" first="5809" last="5819">
<title>Integrins alphavbeta3 and alpha4beta1 act as coreceptors for fractalkine, and the integrin-binding defective mutant of fractalkine is an antagonist of CX3CR1.</title>
<authorList>
<person name="Fujita M."/>
<person name="Takada Y.K."/>
<person name="Takada Y."/>
</authorList>
<dbReference type="PubMed" id="23125415"/>
<dbReference type="DOI" id="10.4049/jimmunol.1200889"/>
</citation>
<scope>FUNCTION</scope>
<scope>BINDING TO CX3CL1</scope>
<scope>IDENTIFICATION IN A COMPLEX WITH CX3CR1 AND CX3CL1</scope>
<scope>CX3CL1-BINDING REGION</scope>
</reference>
<reference key="50">
<citation type="journal article" date="2013" name="J. Gen. Virol." volume="94" first="1723" last="1733">
<title>Integrins modulate the infection efficiency of West Nile virus into cells.</title>
<authorList>
<person name="Schmidt K."/>
<person name="Keller M."/>
<person name="Bader B.L."/>
<person name="Korytar T."/>
<person name="Finke S."/>
<person name="Ziegler U."/>
<person name="Groschup M.H."/>
</authorList>
<dbReference type="PubMed" id="23658209"/>
<dbReference type="DOI" id="10.1099/vir.0.052613-0"/>
</citation>
<scope>FUNCTION (MICROBIAL INFECTION)</scope>
<scope>INTERACTION WITH WEST NILE VIRUS ENVELOPE PROTEIN E</scope>
</reference>
<reference key="51">
<citation type="journal article" date="2014" name="J. Virol." volume="88" first="4338" last="4352">
<title>Roles of the putative integrin-binding motif of the human metapneumovirus fusion (f) protein in cell-cell fusion, viral infectivity, and pathogenesis.</title>
<authorList>
<person name="Wei Y."/>
<person name="Zhang Y."/>
<person name="Cai H."/>
<person name="Mirza A.M."/>
<person name="Iorio R.M."/>
<person name="Peeples M.E."/>
<person name="Niewiesk S."/>
<person name="Li J."/>
</authorList>
<dbReference type="PubMed" id="24478423"/>
<dbReference type="DOI" id="10.1128/jvi.03491-13"/>
</citation>
<scope>FUNCTION (MICROBIAL INFECTION)</scope>
<scope>INTERACTION WITH HUMAN METAPNEUMOVIRUS FUSION PROTEIN</scope>
</reference>
<reference key="52">
<citation type="journal article" date="2014" name="PLoS ONE" volume="9" first="E96372" last="E96372">
<title>The chemokine fractalkine can activate integrins without CX3CR1 through direct binding to a ligand-binding site distinct from the classical RGD-binding site.</title>
<authorList>
<person name="Fujita M."/>
<person name="Takada Y.K."/>
<person name="Takada Y."/>
</authorList>
<dbReference type="PubMed" id="24789099"/>
<dbReference type="DOI" id="10.1371/journal.pone.0096372"/>
</citation>
<scope>BINDING TO CX3CL1</scope>
<scope>CX3CL1-BINDING REGION</scope>
</reference>
<reference key="53">
<citation type="journal article" date="2015" name="J. Biol. Chem." volume="290" first="259" last="271">
<title>Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (site 2) in integrins alphavbeta3, alpha4beta1, and alpha5beta1.</title>
<authorList>
<person name="Fujita M."/>
<person name="Zhu K."/>
<person name="Fujita C.K."/>
<person name="Zhao M."/>
<person name="Lam K.S."/>
<person name="Kurth M.J."/>
<person name="Takada Y.K."/>
<person name="Takada Y."/>
</authorList>
<dbReference type="PubMed" id="25398877"/>
<dbReference type="DOI" id="10.1074/jbc.m114.579946"/>
</citation>
<scope>FUNCTION</scope>
</reference>
<reference key="54">
<citation type="journal article" date="2017" name="Biochem. J." volume="474" first="589" last="596">
<title>The CD9, CD81, and CD151 EC2 domains bind to the classical RGD-binding site of integrin alphavbeta3.</title>
<authorList>
<person name="Yu J."/>
<person name="Lee C.Y."/>
<person name="Changou C.A."/>
<person name="Cedano-Prieto D.M."/>
<person name="Takada Y.K."/>
<person name="Takada Y."/>
</authorList>
<dbReference type="PubMed" id="27993971"/>
<dbReference type="DOI" id="10.1042/bcj20160998"/>
</citation>
<scope>INTERACTION WITH CD9; CD81 AND CD151</scope>
</reference>
<reference key="55">
<citation type="journal article" date="2017" name="Biosci. Rep." volume="37">
<title>The integrin-binding defective FGF2 mutants potently suppress FGF2 signalling and angiogenesis.</title>
<authorList>
<person name="Mori S."/>
<person name="Hatori N."/>
<person name="Kawaguchi N."/>
<person name="Hamada Y."/>
<person name="Shih T.C."/>
<person name="Wu C.Y."/>
<person name="Lam K.S."/>
<person name="Matsuura N."/>
<person name="Yamamoto H."/>
<person name="Takada Y.K."/>
<person name="Takada Y."/>
</authorList>
<dbReference type="PubMed" id="28302677"/>
<dbReference type="DOI" id="10.1042/bsr20170173"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH FGF2</scope>
</reference>
<reference key="56">
<citation type="journal article" date="2017" name="J. Biol. Chem." volume="292" first="20067" last="20075">
<title>Direct binding to integrins and loss of disulfide linkage in interleukin-1beta (IL-1beta) are involved in the agonistic action of IL-1beta.</title>
<authorList>
<person name="Takada Y.K."/>
<person name="Yu J."/>
<person name="Fujita M."/>
<person name="Saegusa J."/>
<person name="Wu C.Y."/>
<person name="Takada Y."/>
</authorList>
<dbReference type="PubMed" id="29030430"/>
<dbReference type="DOI" id="10.1074/jbc.m117.818302"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH IL1B</scope>
</reference>
<reference key="57">
<citation type="journal article" date="2017" name="PLoS ONE" volume="12" first="E0184285" last="E0184285">
<title>Direct integrin binding to insulin-like growth factor-2 through the C-domain is required for insulin-like growth factor receptor type 1 (IGF1R) signaling.</title>
<authorList>
<person name="Cedano Prieto D.M."/>
<person name="Cheng Y."/>
<person name="Chang C.C."/>
<person name="Yu J."/>
<person name="Takada Y.K."/>
<person name="Takada Y."/>
</authorList>
<dbReference type="PubMed" id="28873464"/>
<dbReference type="DOI" id="10.1371/journal.pone.0184285"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH IGF2</scope>
</reference>
<reference key="58">
<citation type="journal article" date="2018" name="Biochem. J." volume="475" first="723" last="732">
<title>Stromal cell-derived factor-1 (CXCL12) activates integrins by direct binding to an allosteric ligand-binding site (site 2) of integrins without CXCR4.</title>
<authorList>
<person name="Fujita M."/>
<person name="Davari P."/>
<person name="Takada Y.K."/>
<person name="Takada Y."/>
</authorList>
<dbReference type="PubMed" id="29301984"/>
<dbReference type="DOI" id="10.1042/bcj20170867"/>
</citation>
<scope>INTERACTION WITH CXCL12</scope>
</reference>
<reference key="59">
<citation type="journal article" date="2019" name="J. Immunol." volume="203" first="1383" last="1391">
<title>Integrin Binding to the Trimeric Interface of CD40L Plays a Critical Role in CD40/CD40L Signaling.</title>
<authorList>
<person name="Takada Y.K."/>
<person name="Yu J."/>
<person name="Shimoda M."/>
<person name="Takada Y."/>
</authorList>
<dbReference type="PubMed" id="31331973"/>
<dbReference type="DOI" id="10.4049/jimmunol.1801630"/>
</citation>
<scope>FUNCTION</scope>
</reference>
<reference key="60">
<citation type="journal article" date="2001" name="Science" volume="294" first="339" last="345">
<title>Crystal structure of the extracellular segment of integrin alpha Vbeta3.</title>
<authorList>
<person name="Xiong J.P."/>
<person name="Stehle T."/>
<person name="Diefenbach B."/>
<person name="Zhang R."/>
<person name="Dunker R."/>
<person name="Scott D.L."/>
<person name="Joachimiak A."/>
<person name="Goodman S.L."/>
<person name="Arnaout M.A."/>
</authorList>
<dbReference type="PubMed" id="11546839"/>
<dbReference type="DOI" id="10.1126/science.1064535"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF 27-718</scope>
<scope>GLYCOSYLATION AT ASN-346; ASN-397; ASN-585 AND ASN-680</scope>
</reference>
<reference key="61">
<citation type="journal article" date="2007" name="J. Mol. Biol." volume="371" first="435" last="446">
<title>Crystallographic structure of the human leukocyte antigen DRA, DRB3*0101: models of a directional alloimmune response and autoimmunity.</title>
<authorList>
<person name="Parry C.S."/>
<person name="Gorski J."/>
<person name="Stern L.J."/>
</authorList>
<dbReference type="PubMed" id="17583734"/>
<dbReference type="DOI" id="10.1016/j.jmb.2007.05.025"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 50-61 (ALLOANTIGEN HPA-1A) IN COMPLEX WITH HLA-DRA/HLA-DRB3 HETERODIMER</scope>
</reference>
<reference key="62">
<citation type="journal article" date="1994" name="Thromb. Haemost." volume="72" first="492" last="502">
<title>Inherited diseases of platelet glycoproteins: considerations for rapid molecular characterization.</title>
<authorList>
<person name="Bray P.F."/>
</authorList>
<dbReference type="PubMed" id="7878622"/>
</citation>
<scope>REVIEW ON GT VARIANTS</scope>
</reference>
<reference key="63">
<citation type="journal article" date="1989" name="J. Clin. Invest." volume="83" first="1778" last="1781">
<title>The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing.</title>
<authorList>
<person name="Newman P.J."/>
<person name="Derbes R.S."/>
<person name="Aster R.H."/>
</authorList>
<dbReference type="PubMed" id="2565345"/>
<dbReference type="DOI" id="10.1172/jci114082"/>
</citation>
<scope>VARIANT HPA-1B PRO-59</scope>
<scope>DESCRIPTION OF ALLOANTIGEN SYSTEM PL(A)</scope>
</reference>
<reference key="64">
<citation type="journal article" date="1992" name="J. Clin. Invest." volume="90" first="2038" last="2043">
<title>An amino acid polymorphism within the RGD binding domain of platelet membrane glycoprotein IIIa is responsible for the formation of the Pena/Penb alloantigen system.</title>
<authorList>
<person name="Wang R."/>
<person name="Furihata K."/>
<person name="McFarland J.G."/>
<person name="Friedman K."/>
<person name="Aster R.H."/>
<person name="Newman P.J."/>
</authorList>
<dbReference type="PubMed" id="1430225"/>
<dbReference type="DOI" id="10.1172/jci116084"/>
</citation>
<scope>VARIANT HPA-4B GLN-169</scope>
<scope>DESCRIPTION OF ALLOANTIGEN SYSTEM PEN</scope>
</reference>
<reference key="65">
<citation type="journal article" date="1993" name="Blood" volume="81" first="70" last="76">
<title>Single point mutation in human glycoprotein IIIa is associated with a new platelet-specific alloantigen (Mo) involved in neonatal alloimmune thrombocytopenia.</title>
<authorList>
<person name="Kuijpers R.W.A.M."/>
<person name="Simsek S."/>
<person name="Faber N.M."/>
<person name="Goldschmeding R."/>
<person name="van Wermerkerken R.K.V."/>
<person name="von Dem Borne A.E.G.K."/>
</authorList>
<dbReference type="PubMed" id="8093349"/>
</citation>
<scope>VARIANT MO(+) ALA-433</scope>
</reference>
<reference key="66">
<citation type="journal article" date="1993" name="Blood" volume="82" first="3386" last="3391">
<title>Amino acid 489 is encoded by a mutational 'hot spot' on the beta 3 integrin chain: the CA/TU human platelet alloantigen system.</title>
<authorList>
<person name="Wang R."/>
<person name="McFarland J.G."/>
<person name="Kekomaki R."/>
<person name="Newman P.J."/>
</authorList>
<dbReference type="PubMed" id="7694683"/>
</citation>
<scope>VARIANT CA(+)/TU(+) GLN-515</scope>
<scope>DESCRIPTION OF ALLOANTIGEN SYSTEM CA/TU</scope>
</reference>
<reference key="67">
<citation type="journal article" date="1994" name="J. Biol. Chem." volume="269" first="8439" last="8444">
<title>A point mutation leads to an unpaired cysteine residue and a molecular weight polymorphism of a functional platelet beta 3 integrin subunit. The Sra alloantigen system of GPIIIa.</title>
<authorList>
<person name="Santoso S."/>
<person name="Kalb R."/>
<person name="Kroll H."/>
<person name="Walka M."/>
<person name="Kiefel V."/>
<person name="Mueller-Eckhardt C."/>
<person name="Newman P.J."/>
</authorList>
<dbReference type="PubMed" id="8132570"/>
</citation>
<scope>VARIANT SR(A) CYS-662</scope>
<scope>DESCRIPTION OF ALLOANTIGEN SYSTEM SR(A)</scope>
</reference>
<reference key="68">
<citation type="journal article" date="1990" name="Science" volume="249" first="915" last="918">
<title>A beta 3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation.</title>
<authorList>
<person name="Loftus J.C."/>
<person name="O'Toole T.E."/>
<person name="Plow E.F."/>
<person name="Glass A."/>
<person name="Frelinger A.L. III"/>
<person name="Ginsberg M.H."/>
</authorList>
<dbReference type="PubMed" id="2392682"/>
<dbReference type="DOI" id="10.1126/science.2392682"/>
</citation>
<scope>VARIANT GT TYR-145</scope>
</reference>
<reference key="69">
<citation type="journal article" date="1992" name="J. Biol. Chem." volume="267" first="3789" last="3794">
<title>A spontaneous mutation of integrin alpha IIb beta 3 (platelet glycoprotein IIb-IIIa) helps define a ligand binding site.</title>
<authorList>
<person name="Bajt M.L."/>
<person name="Ginsberg M.H."/>
<person name="Frelinger A.L. III"/>
<person name="Berndt M.C."/>
<person name="Loftus J.C."/>
</authorList>
<dbReference type="PubMed" id="1371279"/>
</citation>
<scope>VARIANT GT GLN-240</scope>
</reference>
<reference key="70">
<citation type="journal article" date="1992" name="J. Clin. Invest." volume="89" first="1995" last="2004">
<title>A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg--&gt;214Trp mutation.</title>
<authorList>
<person name="Lanza F."/>
<person name="Stierle A."/>
<person name="Fournier D."/>
<person name="Morales M."/>
<person name="Andre G."/>
<person name="Nurden A.T."/>
<person name="Cazenave J.-P."/>
</authorList>
<dbReference type="PubMed" id="1602006"/>
<dbReference type="DOI" id="10.1172/jci115808"/>
</citation>
<scope>VARIANT GT TRP-240</scope>
</reference>
<reference key="71">
<citation type="journal article" date="1992" name="Proc. Natl. Acad. Sci. U.S.A." volume="89" first="10169" last="10173">
<title>Ser-752--&gt;Pro mutation in the cytoplasmic domain of integrin beta 3 subunit and defective activation of platelet integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia.</title>
<authorList>
<person name="Chen Y.-P."/>
<person name="Djaffar I."/>
<person name="Pidard D."/>
<person name="Steiner B."/>
<person name="Cieutat A.-M."/>
<person name="Caen J.P."/>
<person name="Rosa J.-P."/>
</authorList>
<dbReference type="PubMed" id="1438206"/>
<dbReference type="DOI" id="10.1073/pnas.89.21.10169"/>
</citation>
<scope>VARIANT GT PRO-778</scope>
</reference>
<reference key="72">
<citation type="journal article" date="1996" name="Blood" volume="88" first="1666" last="1675">
<title>A Cys374Tyr homozygous mutation of platelet glycoprotein IIIa (beta 3) in a Chinese patient with Glanzmann's thrombasthenia.</title>
<authorList>
<person name="Grimaldi C.M."/>
<person name="Chen F."/>
<person name="Scudder L.E."/>
<person name="Coller B.S."/>
<person name="French D.L."/>
</authorList>
<dbReference type="PubMed" id="8781422"/>
</citation>
<scope>VARIANT GT TYR-400</scope>
</reference>
<reference key="73">
<citation type="journal article" date="1997" name="Blood" volume="90" first="3082" last="3088">
<title>A Leu117--&gt;Trp mutation within the RGD-peptide cross-linking region of beta3 results in Glanzmann thrombasthenia by preventing alphaIIb beta3 export to the platelet surface.</title>
<authorList>
<person name="Basani R.B."/>
<person name="Brown D.L."/>
<person name="Vilaire G."/>
<person name="Bennett J.S."/>
<person name="Poncz M."/>
</authorList>
<dbReference type="PubMed" id="9376589"/>
</citation>
<scope>VARIANT GT TRP-143</scope>
</reference>
<reference key="74">
<citation type="journal article" date="1997" name="Blood Cells Mol. Dis." volume="23" first="39" last="51">
<title>Hematologically important mutations: Glanzmann thrombasthenia.</title>
<authorList>
<person name="French D.L."/>
<person name="Coller B.S."/>
</authorList>
<dbReference type="PubMed" id="9215749"/>
<dbReference type="DOI" id="10.1006/bcmd.1997.0117"/>
</citation>
<scope>VARIANTS GT ASN-145; GLN-242 AND PRO-288</scope>
</reference>
<reference key="75">
<citation type="journal article" date="1998" name="Biochem. Biophys. Res. Commun." volume="251" first="763" last="768">
<title>Three novel integrin beta3 subunit missense mutations (H280P, C560F, and G579S) in thrombasthenia, including one (H280P) prevalent in Japanese patients.</title>
<authorList>
<person name="Ambo H."/>
<person name="Kamata T."/>
<person name="Handa M."/>
<person name="Taki M."/>
<person name="Kuwajima M."/>
<person name="Kawai Y."/>
<person name="Oda A."/>
<person name="Murata M."/>
<person name="Takada Y."/>
<person name="Watanabe K."/>
<person name="Ikeda Y."/>
</authorList>
<dbReference type="PubMed" id="9790984"/>
<dbReference type="DOI" id="10.1006/bbrc.1998.9526"/>
</citation>
<scope>VARIANTS GT PRO-306; PHE-586; SER-598 AND SER-605</scope>
</reference>
<reference key="76">
<citation type="journal article" date="1998" name="Thromb. Haemost." volume="80" first="42" last="48">
<title>A Ser162--&gt;Leu mutation within glycoprotein (GP) IIIa (integrin beta3) results in an unstable alphaIIbbeta3 complex that retains partial function in a novel form of type II Glanzmann thrombasthenia.</title>
<authorList>
<person name="Jackson D.E."/>
<person name="White M.M."/>
<person name="Jennings L.K."/>
<person name="Newman P.J."/>
</authorList>
<dbReference type="PubMed" id="9684783"/>
</citation>
<scope>VARIANT GT LEU-188</scope>
</reference>
<reference key="77">
<citation type="journal article" date="1999" name="Br. J. Haematol." volume="105" first="523" last="531">
<title>Homozygous Cys542--&gt;Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann's thrombasthenia.</title>
<authorList>
<person name="Ruan J."/>
<person name="Schmugge M."/>
<person name="Clemetson K.J."/>
<person name="Cazes E."/>
<person name="Combrie R."/>
<person name="Bourre F."/>
<person name="Nurden A.T."/>
</authorList>
<dbReference type="PubMed" id="10233432"/>
<dbReference type="DOI" id="10.1111/j.1365-2141.1999.01376.x"/>
</citation>
<scope>VARIANT GT ARG-568</scope>
</reference>
<reference key="78">
<citation type="journal article" date="1999" name="Nat. Genet." volume="22" first="231" last="238">
<title>Characterization of single-nucleotide polymorphisms in coding regions of human genes.</title>
<authorList>
<person name="Cargill M."/>
<person name="Altshuler D."/>
<person name="Ireland J."/>
<person name="Sklar P."/>
<person name="Ardlie K."/>
<person name="Patil N."/>
<person name="Shaw N."/>
<person name="Lane C.R."/>
<person name="Lim E.P."/>
<person name="Kalyanaraman N."/>
<person name="Nemesh J."/>
<person name="Ziaugra L."/>
<person name="Friedland L."/>
<person name="Rolfe A."/>
<person name="Warrington J."/>
<person name="Lipshutz R."/>
<person name="Daley G.Q."/>
<person name="Lander E.S."/>
</authorList>
<dbReference type="PubMed" id="10391209"/>
<dbReference type="DOI" id="10.1038/10290"/>
</citation>
<scope>VARIANTS PRO-59; GLN-169 AND ILE-453</scope>
</reference>
<reference key="79">
<citation type="journal article" date="1999" name="Nat. Genet." volume="23" first="373" last="373">
<authorList>
<person name="Cargill M."/>
<person name="Altshuler D."/>
<person name="Ireland J."/>
<person name="Sklar P."/>
<person name="Ardlie K."/>
<person name="Patil N."/>
<person name="Shaw N."/>
<person name="Lane C.R."/>
<person name="Lim E.P."/>
<person name="Kalyanaraman N."/>
<person name="Nemesh J."/>
<person name="Ziaugra L."/>
<person name="Friedland L."/>
<person name="Rolfe A."/>
<person name="Warrington J."/>
<person name="Lipshutz R."/>
<person name="Daley G.Q."/>
<person name="Lander E.S."/>
</authorList>
</citation>
<scope>ERRATUM OF PUBMED:10391209</scope>
</reference>
<reference key="80">
<citation type="journal article" date="2001" name="Blood" volume="98" first="2432" last="2441">
<title>A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (alphaIIbbeta3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype.</title>
<authorList>
<person name="Ruiz C."/>
<person name="Liu C.-Y."/>
<person name="Sun Q.-H."/>
<person name="Sigaud-Fiks M."/>
<person name="Fressinaud E."/>
<person name="Muller J.-Y."/>
<person name="Nurden P."/>
<person name="Nurden A.T."/>
<person name="Newman P.J."/>
<person name="Valentin N."/>
</authorList>
<dbReference type="PubMed" id="11588040"/>
<dbReference type="DOI" id="10.1182/blood.v98.8.2432"/>
</citation>
<scope>VARIANT GT ARG-586</scope>
<scope>CHARACTERIZATION OF VARIANT GT ARG-586</scope>
</reference>
<reference key="81">
<citation type="journal article" date="2002" name="Blood" volume="99" first="4449" last="4456">
<title>A new platelet polymorphism Duv(a+), localized within the RGD binding domain of glycoprotein IIIa, is associated with neonatal thrombocytopenia.</title>
<authorList>
<person name="Jallu V."/>
<person name="Meunier M."/>
<person name="Brement M."/>
<person name="Kaplan C."/>
</authorList>
<dbReference type="PubMed" id="12036875"/>
<dbReference type="DOI" id="10.1182/blood.v99.12.4449"/>
</citation>
<scope>VARIANT ILE-166</scope>
<scope>CHARACTERIZATION OF VARIANT ILE-166</scope>
</reference>
<reference key="82">
<citation type="journal article" date="2002" name="Platelets" volume="13" first="101" last="111">
<title>A novel 196Leu to Pro substitution in the beta3 subunit of the alphaIIbbeta3 integrin in a patient with a variant form of Glanzmann thrombasthenia.</title>
<authorList>
<person name="Nurden A.T."/>
<person name="Ruan J."/>
<person name="Pasquet J.-M."/>
<person name="Gauthier B."/>
<person name="Combrie R."/>
<person name="Kunicki T."/>
<person name="Nurden P."/>
</authorList>
<dbReference type="PubMed" id="11897046"/>
<dbReference type="DOI" id="10.1080/09537100220122466"/>
</citation>
<scope>VARIANT GT PRO-222</scope>
</reference>
<reference key="83">
<citation type="journal article" date="2002" name="Thromb. Haemost." volume="87" first="1034" last="1042">
<title>Glanzmann's thrombasthenia: identification of 19 new mutations in 30 patients.</title>
<authorList>
<person name="D'Andrea G."/>
<person name="Colaizzo D."/>
<person name="Vecchione G."/>
<person name="Grandone E."/>
<person name="Di Minno G."/>
<person name="Margaglione M."/>
</authorList>
<dbReference type="PubMed" id="12083483"/>
</citation>
<scope>VARIANTS GT TRP-119; VAL-243 AND ARG-601</scope>
</reference>
<reference key="84">
<citation type="journal article" date="2002" name="Thromb. Haemost." volume="88" first="503" last="509">
<title>Two new beta3 integrin mutations in Indian patients with Glanzmann thrombasthenia: localization of mutations affecting cysteine residues in integrin beta3.</title>
<authorList>
<person name="Nair S."/>
<person name="Li J."/>
<person name="Mitchell W.B."/>
<person name="Mohanty D."/>
<person name="Coller B.S."/>
<person name="French D.L."/>
</authorList>
<dbReference type="PubMed" id="12353082"/>
<dbReference type="DOI" id="10.1160/th2002880503"/>
</citation>
<scope>VARIANT GT TYR-532</scope>
</reference>
<reference key="85">
<citation type="journal article" date="2004" name="Thromb. Haemost." volume="92" first="1377" last="1386">
<title>A variant thrombasthenic phenotype associated with compound heterozygosity of integrin beta3-subunit: (Met124Val)beta3 alters the subunit dimerization rendering a decreased number of constitutive active alphaIIbbeta3 receptors.</title>
<authorList>
<person name="Gonzalez-Manchon C."/>
<person name="Butta N."/>
<person name="Larrucea S."/>
<person name="Arias-Salgado E.G."/>
<person name="Alonso S."/>
<person name="Lopez A."/>
<person name="Parrilla R."/>
</authorList>
<dbReference type="PubMed" id="15583747"/>
<dbReference type="DOI" id="10.1160/th04-06-0380"/>
</citation>
<scope>VARIANT GT VAL-150</scope>
<scope>CHARACTERIZATION OF VARIANT GT VAL-150</scope>
</reference>
<reference key="86">
<citation type="journal article" date="2005" name="J. Thromb. Haemost." volume="3" first="68" last="73">
<title>Double heterozygosity for a novel missense mutation of Ile304 to Asn in addition to the missense mutation His280 to Pro in the integrin beta3 gene as a cause of the absence of platelet alphaIIbbeta3 in Glanzmann's thrombasthenia.</title>
<authorList>
<person name="Tanaka S."/>
<person name="Hayashi T."/>
<person name="Yoshimura K."/>
<person name="Nakayama M."/>
<person name="Fujita T."/>
<person name="Amano T."/>
<person name="Tani Y."/>
</authorList>
<dbReference type="PubMed" id="15634267"/>
<dbReference type="DOI" id="10.1111/j.1538-7836.2004.00990.x"/>
</citation>
<scope>VARIANTS GT PRO-306 AND ASN-330</scope>
<scope>CHARACTERIZATION OF VARIANT GT ASN-330</scope>
</reference>
<reference key="87">
<citation type="journal article" date="2005" name="J. Thromb. Haemost." volume="3" first="482" last="488">
<title>Mutations in GPIIIa molecule as a cause for Glanzmann thrombasthenia in Indian patients.</title>
<authorList>
<person name="Nair S."/>
<person name="Ghosh K."/>
<person name="Shetty S."/>
<person name="Mohanty D."/>
</authorList>
<dbReference type="PubMed" id="15748237"/>
<dbReference type="DOI" id="10.1111/j.1538-7836.2005.01159.x"/>
</citation>
<scope>VARIANTS GT CYS-141 AND LEU-321</scope>
</reference>
<reference key="88">
<citation type="journal article" date="2008" name="Blood" volume="111" first="3407" last="3414">
<title>A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the alphaIIbbeta3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia.</title>
<authorList>
<person name="Ghevaert C."/>
<person name="Salsmann A."/>
<person name="Watkins N.A."/>
<person name="Schaffner-Reckinger E."/>
<person name="Rankin A."/>
<person name="Garner S.F."/>
<person name="Stephens J."/>
<person name="Smith G.A."/>
<person name="Debili N."/>
<person name="Vainchenker W."/>
<person name="de Groot P.G."/>
<person name="Huntington J.A."/>
<person name="Laffan M."/>
<person name="Kieffer N."/>
<person name="Ouwehand W.H."/>
</authorList>
<dbReference type="PubMed" id="18065693"/>
<dbReference type="DOI" id="10.1182/blood-2007-09-112615"/>
</citation>
<scope>VARIANT BDPLT16 HIS-749</scope>
<scope>CHARACTERIZATION OF VARIANT BDPLT16 HIS-749</scope>
</reference>
<reference key="89">
<citation type="journal article" date="2010" name="Hum. Mutat." volume="31" first="237" last="246">
<title>AlphaIIbbeta3 integrin: new allelic variants in Glanzmann thrombasthenia, effects on ITGA2B and ITGB3 mRNA splicing, expression, and structure-function.</title>
<authorList>
<person name="Jallu V."/>
<person name="Dusseaux M."/>
<person name="Panzer S."/>
<person name="Torchet M.F."/>
<person name="Hezard N."/>
<person name="Goudemand J."/>
<person name="de Brevern A.G."/>
<person name="Kaplan C."/>
</authorList>
<dbReference type="PubMed" id="20020534"/>
<dbReference type="DOI" id="10.1002/humu.21179"/>
</citation>
<scope>VARIANTS GT TYR-64; ARG-144; PRO-222; ASP-247 AND MET-279</scope>
<scope>CHARACTERIZATION OF VARIANTS TYR-64; PRO-222; ASP-247 AND MET-279</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="90">
<citation type="journal article" date="2017" name="Blood Coagul. Fibrinolysis" volume="28" first="681" last="686">
<title>Molecular characterization of Glanzmann's thrombasthenia in Iran: identification of three novel mutations.</title>
<authorList>
<person name="Kazemi A."/>
<person name="Abolghasemi H."/>
<person name="Kazemzadeh S."/>
<person name="Vahidi R."/>
<person name="Faranoush M."/>
<person name="Farsinejad A."/>
<person name="Ala F."/>
</authorList>
<dbReference type="PubMed" id="29084015"/>
<dbReference type="DOI" id="10.1097/mbc.0000000000000673"/>
</citation>
<scope>VARIANT GT GLN-240</scope>
<scope>VARIANT PRO-59</scope>
</reference>
<reference key="91">
<citation type="journal article" date="2018" name="Ann. Hematol." volume="97" first="629" last="640">
<title>A novel heterozygous ITGB3 p.T720del inducing spontaneous activation of integrin alphaIIbbeta3 in autosomal dominant macrothrombocytopenia with aggregation dysfunction.</title>
<authorList>
<person name="Miyashita N."/>
<person name="Onozawa M."/>
<person name="Hayasaka K."/>
<person name="Yamada T."/>
<person name="Migita O."/>
<person name="Hata K."/>
<person name="Okada K."/>
<person name="Goto H."/>
<person name="Nakagawa M."/>
<person name="Hashimoto D."/>
<person name="Kahata K."/>
<person name="Kondo T."/>
<person name="Kunishima S."/>
<person name="Teshima T."/>
</authorList>
<dbReference type="PubMed" id="29380037"/>
<dbReference type="DOI" id="10.1007/s00277-017-3214-4"/>
</citation>
<scope>VARIANT BDPLT16 THR-746 DEL</scope>
<scope>CHARACTERIZATION OF VARIANTS BDPLT16 THR-746 DEL AND HIS-749</scope>
</reference>
<comment type="function">
<text evidence="21 37 56 57 60 63 66 70 71 74 75 76 80 87 94 95">Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets (By similarity). ITGAV:ITGB3 binds to fractalkine (CX3CL1) and acts as its coreceptor in CX3CR1-dependent fractalkine signaling (PubMed:23125415, PubMed:24789099). ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling (PubMed:20682778). ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling (PubMed:18441324). ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling (PubMed:28302677). ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling (PubMed:19578119). ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling (PubMed:28873464). ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling (PubMed:29030430). ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGAV:ITGB3 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887). In brain, plays a role in synaptic transmission and plasticity. Involved in the regulation of the serotonin neurotransmission, is required to localize to specific compartments within the synapse the serotonin receptor SLC6A4 and for an appropriate reuptake of serotonin. Controls excitatory synaptic strength by regulating GRIA2-containing AMPAR endocytosis, which affects AMPAR abundance and composition (By similarity). ITGAV:ITGB3 act as a receptor for CD40LG (PubMed:31331973).</text>
</comment>
<comment type="function">
<text evidence="54">(Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for Herpes virus 8/HHV-8.</text>
</comment>
<comment type="function">
<text evidence="81">(Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for Coxsackievirus A9.</text>
</comment>
<comment type="function">
<text evidence="90">(Microbial infection) Acts as a receptor for Hantaan virus.</text>
</comment>
<comment type="function">
<text evidence="46">(Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for Cytomegalovirus/HHV-5.</text>
</comment>
<comment type="function">
<text evidence="69">(Microbial infection) Integrin ITGA5:ITGB3 acts as a receptor for Human metapneumovirus.</text>
</comment>
<comment type="function">
<text evidence="27">(Microbial infection) Integrin ITGAV:ITGB3 acts aP05556s a receptor for Human parechovirus 1.</text>
</comment>
<comment type="function">
<text evidence="67">(Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for West nile virus.</text>
</comment>
<comment type="function">
<text evidence="25">(Microbial infection) In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.</text>
</comment>
<comment type="subunit">
<text evidence="21 30 32 36 37 41 42 48 49 53 56 58 60 63 64 65 66 73 74 75 76 78">Heterodimer of an alpha and a beta subunit. Beta-3 (ITGB3) associates with either alpha-IIb (ITGA2B) or alpha-V (ITGAV). Isoform Beta-3C interacts with FLNB. Interacts with COMP. Interacts with PDIA6 following platelet stimulation. Interacts with SYK; upon activation by ITGB3 promotes platelet adhesion. Interacts with MYO10. Interacts with DAB2. Interacts with FERMT2. Interacts with EMP2; regulates the levels of the heterodimer ITGA5:ITGB3 integrin expression on the plasma membrane (PubMed:16216233). Integrin ITGAV:ITGB3 interacts with FBLN5 (via N-terminus) (By similarity). ITGAV:ITGB3 interacts with CCN3 (PubMed:12695522). ITGAV:ITGB3 is found in a ternary complex with CX3CR1 and CX3CL1 (PubMed:23125415). ITGAV:ITGB3 is found in a ternary complex with NRG1 and ERBB3 (PubMed:20682778). ITGAV:ITGB3 is found in a ternary complex with FGF1 and FGFR1 (PubMed:18441324). ITGAV:ITGB3 interacts with FGF2; it is likely that FGF2 can simultaneously bind ITGAV:ITGB3 and FGF receptors (PubMed:28302677). ITGAV:ITGB3 binds to IL1B (PubMed:29030430). ITGAV:ITGB3 is found in a ternary complex with IGF1 and IGF1R (PubMed:19578119). ITGAV:ITGB3 interacts with IGF2 (PubMed:28873464). ITGAV:ITGB3 interacts with FBN1 (PubMed:12807887). ITGAV:ITGB3 interacts with CD9, CD81 and CD151 (via second extracellular domain) (PubMed:27993971). Interacts (via the allosteric site (site 2)) with CXCL12 in a CXCR4-independent manner (PubMed:29301984). Interacts with MXRA8/DICAM; the interaction inhibits ITGAV:ITGB3 heterodimer formation (PubMed:22492581). ITGAV:ITGB3 interacts with PTN (PubMed:19141530). Forms a complex with PTPRZ1 and PTN that stimulates endothelial cell migration through ITGB3 Tyr-773 phosphorylation (PubMed:19141530). ITGAV:ITGB3 interacts with SLC6A4 (By similarity). ITGA2B:ITGB3 interacts with PPIA/CYPA; the interaction is ROS and PPIase activity-dependent and is increased in the presence of thrombin (By similarity).</text>
</comment>
<comment type="subunit">
<text evidence="54">(Microbial infection) Integrin ITGAV:ITGB3 interacts with herpes virus 8/HHV-8 glycoprotein B.</text>
</comment>
<comment type="subunit">
<text evidence="81">(Microbial infection) Integrin ITGAV:ITGB3 interacts with coxsackievirus A9 capsid proteins.</text>
</comment>
<comment type="subunit">
<text evidence="90">(Microbial infection) Interacts with Hantaan virus glycoprotein G.</text>
</comment>
<comment type="subunit">
<text evidence="46">(Microbial infection) Integrin ITGAV:ITGB3 interacts with cytomegalovirus/HHV-5 gH:gL proteins.</text>
</comment>
<comment type="subunit">
<text evidence="69">(Microbial infection) Integrin ITGA5:ITGB3 interacts with human metapneumovirus fusion protein.</text>
</comment>
<comment type="subunit">
<text evidence="27">(Microbial infection) Integrin ITGAV:ITGB3 interacts with human parechovirus 1 capsid proteins.</text>
</comment>
<comment type="subunit">
<text evidence="67">(Microbial infection) Integrin ITGAV:ITGB3 interacts with west nile virus envelope protein E.</text>
</comment>
<comment type="subunit">
<text evidence="25 52">(Microbial infection) Interacts with HIV-1 Tat (PubMed:10397733). ITGAV:ITGB3 interacts with AGRA2 (PubMed:16982628).</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-702847">
<id>P05106</id>
</interactant>
<interactant intactId="EBI-15188013">
<id>P78423</id>
<label>CX3CL1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>7</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-702847">
<id>P05106</id>
</interactant>
<interactant intactId="EBI-350432">
<id>P21333</id>
<label>FLNA</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-702847">
<id>P05106</id>
</interactant>
<interactant intactId="EBI-702693">
<id>P08514</id>
<label>ITGA2B</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>11</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-702847">
<id>P05106</id>
</interactant>
<interactant intactId="EBI-15805658">
<id>P08514-1</id>
<label>ITGA2B</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-702847">
<id>P05106</id>
</interactant>
<interactant intactId="EBI-298282">
<id>P06756</id>
<label>ITGAV</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>13</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-702847">
<id>P05106</id>
</interactant>
<interactant intactId="EBI-702847">
<id>P05106</id>
<label>ITGB3</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-702847">
<id>P05106</id>
</interactant>
<interactant intactId="EBI-16414951">
<id>PRO_0000022750</id>
<label>PLA2G2A</label>
<dbReference type="UniProtKB" id="P14555"/>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-702847">
<id>P05106</id>
</interactant>
<interactant intactId="EBI-968788">
<id>P18031</id>
<label>PTPN1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-702847">
<id>P05106</id>
</interactant>
<interactant intactId="EBI-2462036">
<id>Q9Y490</id>
<label>TLN1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-702847">
<id>P05106</id>
</interactant>
<interactant intactId="EBI-5847257">
<id>P05094</id>
<label>ACTN1</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-702847">
<id>P05106</id>
</interactant>
<interactant intactId="EBI-9027696">
<id>F5HB81</id>
<label>gB</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-702847">
<id>P05106</id>
</interactant>
<interactant intactId="EBI-6903636">
<id>Q62101</id>
<label>Prkd1</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-702847">
<id>P05106</id>
</interactant>
<interactant intactId="EBI-298680">
<id>P05480</id>
<label>Src</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-702847">
<id>P05106</id>
</interactant>
<interactant intactId="EBI-1039593">
<id>P26039</id>
<label>Tln1</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>7</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-702847">
<id>P05106</id>
</interactant>
<interactant intactId="EBI-1035421">
<id>P54939</id>
<label>TLN1</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-702847">
<id>P05106</id>
</interactant>
<interactant intactId="EBI-981051">
<id>P06935</id>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location evidence="62 64 87">Cell membrane</location>
<topology evidence="62 64 87">Single-pass type I membrane protein</topology>
</subcellularLocation>
<subcellularLocation>
<location evidence="64">Cell projection</location>
<location evidence="64">Lamellipodium membrane</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="64">Cell junction</location>
<location evidence="64">Focal adhesion</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="21">Cell junction</location>
<location evidence="21">Synapse</location>
<location evidence="21">Postsynaptic cell membrane</location>
<topology evidence="21">Single-pass type I membrane protein</topology>
</subcellularLocation>
<subcellularLocation>
<location evidence="21">Cell junction</location>
<location evidence="21">Synapse</location>
</subcellularLocation>
</comment>
<comment type="alternative products">
<event type="alternative splicing"/>
<isoform>
<id>P05106-1</id>
<name>Beta-3A</name>
<sequence type="displayed"/>
</isoform>
<isoform>
<id>P05106-2</id>
<name>Beta-3B</name>
<sequence type="described" ref="VSP_002745"/>
</isoform>
<isoform>
<id>P05106-3</id>
<name>Beta-3C</name>
<sequence type="described" ref="VSP_002746"/>
</isoform>
</comment>
<comment type="tissue specificity">
<text>Isoform beta-3A and isoform beta-3C are widely expressed. Isoform beta-3A is specifically expressed in osteoblast cells; isoform beta-3C is specifically expressed in prostate and testis.</text>
</comment>
<comment type="PTM">
<text evidence="26">Phosphorylated on tyrosine residues in response to thrombin-induced platelet aggregation. Probably involved in outside-in signaling. A peptide (AA 740-762) is capable of binding GRB2 only when both Tyr-773 and Tyr-785 are phosphorylated. Phosphorylation of Thr-779 inhibits SHC binding.</text>
</comment>
<comment type="polymorphism">
<text>Position 59 is associated with platelet-specific alloantigen HPA-1 (ZW or PL(A)). HPA-1A/ZW(A)/PL(A1) has Leu-59 and HPA-1B/ZW(B)/PL(A2) has Pro-59. HPA-1A is involved in fetal-maternal alloimmune thromobocytopenia (FMAIT) as well as in neonatal alloimmune thrombocytopenia (NAIT).</text>
</comment>
<comment type="polymorphism">
<text>Position 169 is associated with platelet-specific alloantigen HPA-4 (PEN or YUK). HPA-4A/PEN(A)/YUK(A) has Arg-169 and HPA-4B/PEN(B)/YUK(B) has Gln-169. HPA-4B is involved in neonatal alloimmune thrombocytopenia (NAIT or NATP).</text>
</comment>
<comment type="polymorphism">
<text>Position 433 is associated with platelet-specific alloantigen MO. MO(-) has Pro-433 and MO(+) has Ala-433. MO(+) is involved in NAIT.</text>
</comment>
<comment type="polymorphism">
<text>Position 515 is associated with platelet-specific alloantigen CA/TU. CA(-)/TU(-) has Arg-515 and CA(+)/TU(+) has Gln-515. CA(+) is involved in NAIT.</text>
</comment>
<comment type="polymorphism">
<text>Position 662 is associated with platelet-specific alloantigen SR(A). SR(A)(-) has Arg-662 and SR(A)(+) has Cys-662.</text>
</comment>
<comment type="disease" evidence="23 29 31 34 35 38 40 43 44 45 47 62 68 77 86 88 89 91 92">
<disease id="DI-01664">
<name>Glanzmann thrombasthenia</name>
<acronym>GT</acronym>
<description>A common inherited disease of platelet aggregation. It is characterized by mucocutaneous bleeding of mild-to-moderate severity. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb-IIIa complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the GPIIb-IIIa complex at reduced levels, have detectable amounts of fibrinogen, and have low or moderate clot retraction capability.</description>
<dbReference type="MIM" id="273800"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="55 79">
<disease id="DI-03752">
<name>Bleeding disorder, platelet-type 16</name>
<acronym>BDPLT16</acronym>
<description>An autosomal dominant form of congenital macrothrombocytopenia associated with platelet anisocytosis. It is a disorder of platelet production. Affected individuals may have no or only mildly increased bleeding tendency. In vitro studies show mild platelet functional abnormalities.</description>
<dbReference type="MIM" id="187800"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="similarity">
<text evidence="98">Belongs to the integrin beta chain family.</text>
</comment>
<comment type="online information" name="SHMPD">
<link uri="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&amp;genename=ITGB3"/>
<text>The Singapore human mutation and polymorphism database</text>
</comment>
<dbReference type="EMBL" id="J02703">
<property type="protein sequence ID" value="AAA52589.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="M20311">
<property type="protein sequence ID" value="AAA60122.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="M35999">
<property type="protein sequence ID" value="AAA35927.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="U95204">
<property type="protein sequence ID" value="AAB71380.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="CH471231">
<property type="protein sequence ID" value="EAW57682.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC127666">
<property type="protein sequence ID" value="AAI27667.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC127667">
<property type="protein sequence ID" value="AAI27668.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="L28832">
<property type="protein sequence ID" value="AAA20880.2"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32686">
<property type="protein sequence ID" value="AAA67537.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32667">
<property type="protein sequence ID" value="AAA67537.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32672">
<property type="protein sequence ID" value="AAA67537.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32673">
<property type="protein sequence ID" value="AAA67537.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32674">
<property type="protein sequence ID" value="AAA67537.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32675">
<property type="protein sequence ID" value="AAA67537.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32680">
<property type="protein sequence ID" value="AAA67537.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32681">
<property type="protein sequence ID" value="AAA67537.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32682">
<property type="protein sequence ID" value="AAA67537.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32685">
<property type="protein sequence ID" value="AAA67537.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M57494">
<property type="protein sequence ID" value="AAA52600.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M57481">
<property type="protein sequence ID" value="AAA52600.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M57482">
<property type="protein sequence ID" value="AAA52600.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M57483">
<property type="protein sequence ID" value="AAA52600.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M57484">
<property type="protein sequence ID" value="AAA52600.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M57485">
<property type="protein sequence ID" value="AAA52600.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M57486">
<property type="protein sequence ID" value="AAA52600.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M57487">
<property type="protein sequence ID" value="AAA52600.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M57488">
<property type="protein sequence ID" value="AAA52600.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M57489">
<property type="protein sequence ID" value="AAA52600.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M57490">
<property type="protein sequence ID" value="AAA52600.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M57491">
<property type="protein sequence ID" value="AAA52600.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M57492">
<property type="protein sequence ID" value="AAA52600.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M57493">
<property type="protein sequence ID" value="AAA52600.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="U03881">
<property type="protein sequence ID" value="AAA16076.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="S49379">
<property type="protein sequence ID" value="AAB23689.2"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M25108">
<property type="protein sequence ID" value="AAA36121.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS11511.1">
<molecule id="P05106-1"/>
</dbReference>
<dbReference type="PIR" id="A26547">
<property type="entry name" value="A26547"/>
</dbReference>
<dbReference type="PIR" id="A60798">
<property type="entry name" value="A60798"/>
</dbReference>
<dbReference type="PIR" id="B36268">
<property type="entry name" value="B36268"/>
</dbReference>
<dbReference type="PIR" id="I77349">
<property type="entry name" value="I77349"/>
</dbReference>
<dbReference type="PIR" id="S14324">
<property type="entry name" value="S14324"/>
</dbReference>
<dbReference type="RefSeq" id="NP_000203.2">
<molecule id="P05106-1"/>
<property type="nucleotide sequence ID" value="NM_000212.2"/>
</dbReference>
<dbReference type="PDB" id="1JV2">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.10"/>
<property type="chains" value="B=27-718"/>
</dbReference>
<dbReference type="PDB" id="1KUP">
<property type="method" value="NMR"/>
<property type="chains" value="B=742-766"/>
</dbReference>
<dbReference type="PDB" id="1KUZ">
<property type="method" value="NMR"/>
<property type="chains" value="B=742-766"/>
</dbReference>
<dbReference type="PDB" id="1L5G">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.20"/>
<property type="chains" value="B=27-718"/>
</dbReference>
<dbReference type="PDB" id="1M1X">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.30"/>
<property type="chains" value="B=27-718"/>
</dbReference>
<dbReference type="PDB" id="1M8O">
<property type="method" value="NMR"/>
<property type="chains" value="B=742-788"/>
</dbReference>
<dbReference type="PDB" id="1MIZ">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.90"/>
<property type="chains" value="A=765-769"/>
</dbReference>
<dbReference type="PDB" id="1MK7">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="A/C=765-775"/>
</dbReference>
<dbReference type="PDB" id="1MK9">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="A/C/E/G=765-776"/>
</dbReference>
<dbReference type="PDB" id="1RN0">
<property type="method" value="Model"/>
<property type="chains" value="B=135-378"/>
</dbReference>
<dbReference type="PDB" id="1S4X">
<property type="method" value="NMR"/>
<property type="chains" value="A=742-788"/>
</dbReference>
<dbReference type="PDB" id="1TYE">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.90"/>
<property type="chains" value="B/D/F=27-466"/>
</dbReference>
<dbReference type="PDB" id="1U8C">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.10"/>
<property type="chains" value="B=27-718"/>
</dbReference>
<dbReference type="PDB" id="2INI">
<property type="method" value="Model"/>
<property type="chains" value="B=81-460, B=558-716"/>
</dbReference>
<dbReference type="PDB" id="2K9J">
<property type="method" value="NMR"/>
<property type="chains" value="B=711-753"/>
</dbReference>
<dbReference type="PDB" id="2KNC">
<property type="method" value="NMR"/>
<property type="chains" value="B=715-788"/>
</dbReference>
<dbReference type="PDB" id="2KV9">
<property type="method" value="NMR"/>
<property type="chains" value="B=739-788"/>
</dbReference>
<dbReference type="PDB" id="2L1C">
<property type="method" value="NMR"/>
<property type="chains" value="B=762-788"/>
</dbReference>
<dbReference type="PDB" id="2L91">
<property type="method" value="NMR"/>
<property type="chains" value="A=711-753"/>
</dbReference>
<dbReference type="PDB" id="2LJD">
<property type="method" value="NMR"/>
<property type="chains" value="A=742-788"/>
</dbReference>
<dbReference type="PDB" id="2LJE">
<property type="method" value="NMR"/>
<property type="chains" value="A=742-788"/>
</dbReference>
<dbReference type="PDB" id="2LJF">
<property type="method" value="NMR"/>
<property type="chains" value="A=742-788"/>
</dbReference>
<dbReference type="PDB" id="2MTP">
<property type="method" value="NMR"/>
<property type="chains" value="C=742-788"/>
</dbReference>
<dbReference type="PDB" id="2N9Y">
<property type="method" value="NMR"/>
<property type="chains" value="B=712-753"/>
</dbReference>
<dbReference type="PDB" id="2Q6W">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.25"/>
<property type="chains" value="C/F=50-61"/>
</dbReference>
<dbReference type="PDB" id="2RMZ">
<property type="method" value="NMR"/>
<property type="chains" value="A=711-753"/>
</dbReference>
<dbReference type="PDB" id="2RN0">
<property type="method" value="NMR"/>
<property type="chains" value="A=711-753"/>
</dbReference>
<dbReference type="PDB" id="2VC2">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.10"/>
<property type="chains" value="B=27-487"/>
</dbReference>
<dbReference type="PDB" id="2VDK">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="B=27-487"/>
</dbReference>
<dbReference type="PDB" id="2VDL">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.75"/>
<property type="chains" value="B=27-487"/>
</dbReference>
<dbReference type="PDB" id="2VDM">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.90"/>
<property type="chains" value="B=27-487"/>
</dbReference>
<dbReference type="PDB" id="2VDN">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.90"/>
<property type="chains" value="B=27-487"/>
</dbReference>
<dbReference type="PDB" id="2VDO">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.51"/>
<property type="chains" value="B=27-487"/>
</dbReference>
<dbReference type="PDB" id="2VDP">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="B=27-487"/>
</dbReference>
<dbReference type="PDB" id="2VDQ">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.59"/>
<property type="chains" value="B=27-487"/>
</dbReference>
<dbReference type="PDB" id="2VDR">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.40"/>
<property type="chains" value="B=27-487"/>
</dbReference>
<dbReference type="PDB" id="3FCS">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.55"/>
<property type="chains" value="B/D=27-716"/>
</dbReference>
<dbReference type="PDB" id="3FCU">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.90"/>
<property type="chains" value="B/D/F=27-487"/>
</dbReference>
<dbReference type="PDB" id="3IJE">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.90"/>
<property type="chains" value="B=27-721"/>
</dbReference>
<dbReference type="PDB" id="3NID">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.30"/>
<property type="chains" value="B/D=27-497"/>
</dbReference>
<dbReference type="PDB" id="3NIF">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.40"/>
<property type="chains" value="B/D=27-497"/>
</dbReference>
<dbReference type="PDB" id="3NIG">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.25"/>
<property type="chains" value="B/D=27-497"/>
</dbReference>
<dbReference type="PDB" id="3T3M">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.60"/>
<property type="chains" value="B/D=27-498"/>
</dbReference>
<dbReference type="PDB" id="3T3P">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="B/D=27-498"/>
</dbReference>
<dbReference type="PDB" id="3ZDX">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.45"/>
<property type="chains" value="B/D=27-498"/>
</dbReference>
<dbReference type="PDB" id="3ZDY">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.45"/>
<property type="chains" value="B/D=27-498"/>
</dbReference>
<dbReference type="PDB" id="3ZDZ">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.75"/>
<property type="chains" value="B/D=27-498"/>
</dbReference>
<dbReference type="PDB" id="3ZE0">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.95"/>
<property type="chains" value="B/D=27-498"/>
</dbReference>
<dbReference type="PDB" id="3ZE1">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.00"/>
<property type="chains" value="B/D=27-498"/>
</dbReference>
<dbReference type="PDB" id="3ZE2">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.35"/>
<property type="chains" value="B/D=27-498"/>
</dbReference>
<dbReference type="PDB" id="4CAK">
<property type="method" value="EM"/>
<property type="resolution" value="20.50"/>
<property type="chains" value="B=27-716"/>
</dbReference>
<dbReference type="PDB" id="4G1E">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.00"/>
<property type="chains" value="B=27-717"/>
</dbReference>
<dbReference type="PDB" id="4G1M">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.90"/>
<property type="chains" value="B=27-718"/>
</dbReference>
<dbReference type="PDB" id="4MMX">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.32"/>
<property type="chains" value="B=27-718"/>
</dbReference>
<dbReference type="PDB" id="4MMY">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.18"/>
<property type="chains" value="B=27-718"/>
</dbReference>
<dbReference type="PDB" id="4MMZ">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.10"/>
<property type="chains" value="B=27-718"/>
</dbReference>
<dbReference type="PDB" id="4O02">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.60"/>
<property type="chains" value="B=27-718"/>
</dbReference>
<dbReference type="PDB" id="4Z7N">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.60"/>
<property type="chains" value="B/D=29-497"/>
</dbReference>
<dbReference type="PDB" id="4Z7O">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.85"/>
<property type="chains" value="B/D=29-497"/>
</dbReference>
<dbReference type="PDB" id="4Z7Q">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.70"/>
<property type="chains" value="B/D=27-497"/>
</dbReference>
<dbReference type="PDB" id="5HDB">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.70"/>
<property type="chains" value="B/D=27-497"/>
</dbReference>
<dbReference type="PDB" id="6AVQ">
<property type="method" value="EM"/>
<property type="resolution" value="35.00"/>
<property type="chains" value="B=27-718"/>
</dbReference>
<dbReference type="PDB" id="6AVR">
<property type="method" value="EM"/>
<property type="resolution" value="35.00"/>
<property type="chains" value="B=27-718"/>
</dbReference>
<dbReference type="PDB" id="6AVU">
<property type="method" value="EM"/>
<property type="resolution" value="35.00"/>
<property type="chains" value="B=27-718"/>
</dbReference>
<dbReference type="PDB" id="6BXB">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.39"/>
<property type="chains" value="A/B=27-135, A/B=378-548"/>
</dbReference>
<dbReference type="PDB" id="6BXF">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.20"/>
<property type="chains" value="A/B=27-135, A/B=378-548"/>
</dbReference>
<dbReference type="PDB" id="6BXJ">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.09"/>
<property type="chains" value="A=27-135, A=378-714"/>
</dbReference>
<dbReference type="PDB" id="6CKB">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="A/B=27-135, A/B=378-548"/>
</dbReference>
<dbReference type="PDB" id="6MK0">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.00"/>
<property type="chains" value="B=30-716"/>
</dbReference>
<dbReference type="PDB" id="6MSL">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.10"/>
<property type="chains" value="B=27-721"/>
</dbReference>
<dbReference type="PDB" id="6MSU">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.11"/>
<property type="chains" value="B=27-721"/>
</dbReference>
<dbReference type="PDB" id="6NAJ">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.10"/>
<property type="chains" value="B=27-716"/>
</dbReference>
<dbReference type="PDB" id="6V4P">
<property type="method" value="EM"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="B=1-690"/>
</dbReference>
<dbReference type="PDBsum" id="1JV2"/>
<dbReference type="PDBsum" id="1KUP"/>
<dbReference type="PDBsum" id="1KUZ"/>
<dbReference type="PDBsum" id="1L5G"/>
<dbReference type="PDBsum" id="1M1X"/>
<dbReference type="PDBsum" id="1M8O"/>
<dbReference type="PDBsum" id="1MIZ"/>
<dbReference type="PDBsum" id="1MK7"/>
<dbReference type="PDBsum" id="1MK9"/>
<dbReference type="PDBsum" id="1RN0"/>
<dbReference type="PDBsum" id="1S4X"/>
<dbReference type="PDBsum" id="1TYE"/>
<dbReference type="PDBsum" id="1U8C"/>
<dbReference type="PDBsum" id="2INI"/>
<dbReference type="PDBsum" id="2K9J"/>
<dbReference type="PDBsum" id="2KNC"/>
<dbReference type="PDBsum" id="2KV9"/>
<dbReference type="PDBsum" id="2L1C"/>
<dbReference type="PDBsum" id="2L91"/>
<dbReference type="PDBsum" id="2LJD"/>
<dbReference type="PDBsum" id="2LJE"/>
<dbReference type="PDBsum" id="2LJF"/>
<dbReference type="PDBsum" id="2MTP"/>
<dbReference type="PDBsum" id="2N9Y"/>
<dbReference type="PDBsum" id="2Q6W"/>
<dbReference type="PDBsum" id="2RMZ"/>
<dbReference type="PDBsum" id="2RN0"/>
<dbReference type="PDBsum" id="2VC2"/>
<dbReference type="PDBsum" id="2VDK"/>
<dbReference type="PDBsum" id="2VDL"/>
<dbReference type="PDBsum" id="2VDM"/>
<dbReference type="PDBsum" id="2VDN"/>
<dbReference type="PDBsum" id="2VDO"/>
<dbReference type="PDBsum" id="2VDP"/>
<dbReference type="PDBsum" id="2VDQ"/>
<dbReference type="PDBsum" id="2VDR"/>
<dbReference type="PDBsum" id="3FCS"/>
<dbReference type="PDBsum" id="3FCU"/>
<dbReference type="PDBsum" id="3IJE"/>
<dbReference type="PDBsum" id="3NID"/>
<dbReference type="PDBsum" id="3NIF"/>
<dbReference type="PDBsum" id="3NIG"/>
<dbReference type="PDBsum" id="3T3M"/>
<dbReference type="PDBsum" id="3T3P"/>
<dbReference type="PDBsum" id="3ZDX"/>
<dbReference type="PDBsum" id="3ZDY"/>
<dbReference type="PDBsum" id="3ZDZ"/>
<dbReference type="PDBsum" id="3ZE0"/>
<dbReference type="PDBsum" id="3ZE1"/>
<dbReference type="PDBsum" id="3ZE2"/>
<dbReference type="PDBsum" id="4CAK"/>
<dbReference type="PDBsum" id="4G1E"/>
<dbReference type="PDBsum" id="4G1M"/>
<dbReference type="PDBsum" id="4MMX"/>
<dbReference type="PDBsum" id="4MMY"/>
<dbReference type="PDBsum" id="4MMZ"/>
<dbReference type="PDBsum" id="4O02"/>
<dbReference type="PDBsum" id="4Z7N"/>
<dbReference type="PDBsum" id="4Z7O"/>
<dbReference type="PDBsum" id="4Z7Q"/>
<dbReference type="PDBsum" id="5HDB"/>
<dbReference type="PDBsum" id="6AVQ"/>
<dbReference type="PDBsum" id="6AVR"/>
<dbReference type="PDBsum" id="6AVU"/>
<dbReference type="PDBsum" id="6BXB"/>
<dbReference type="PDBsum" id="6BXF"/>
<dbReference type="PDBsum" id="6BXJ"/>
<dbReference type="PDBsum" id="6CKB"/>
<dbReference type="PDBsum" id="6MK0"/>
<dbReference type="PDBsum" id="6MSL"/>
<dbReference type="PDBsum" id="6MSU"/>
<dbReference type="PDBsum" id="6NAJ"/>
<dbReference type="PDBsum" id="6V4P"/>
<dbReference type="BMRB" id="P05106"/>
<dbReference type="SMR" id="P05106"/>
<dbReference type="BioGRID" id="109896">
<property type="interactions" value="48"/>
</dbReference>
<dbReference type="ComplexPortal" id="CPX-1795">
<property type="entry name" value="Integrin alphav-beta3 complex"/>
</dbReference>
<dbReference type="ComplexPortal" id="CPX-1799">
<property type="entry name" value="Integrin alphaIIb-beta3 complex"/>
</dbReference>
<dbReference type="CORUM" id="P05106"/>
<dbReference type="DIP" id="DIP-304N"/>
<dbReference type="ELM" id="P05106"/>
<dbReference type="IntAct" id="P05106">
<property type="interactions" value="28"/>
</dbReference>
<dbReference type="MINT" id="P05106"/>
<dbReference type="STRING" id="9606.ENSP00000452786"/>
<dbReference type="BindingDB" id="P05106"/>
<dbReference type="ChEMBL" id="CHEMBL1907598"/>
<dbReference type="ChEMBL" id="CHEMBL2093869"/>
<dbReference type="ChEMBL" id="CHEMBL2111461"/>
<dbReference type="ChEMBL" id="CHEMBL3883284"/>
<dbReference type="ChEMBL" id="CHEMBL4106150"/>
<dbReference type="DrugBank" id="DB00054">
<property type="generic name" value="Abciximab"/>
</dbReference>
<dbReference type="DrugBank" id="DB00098">
<property type="generic name" value="Antithymocyte immunoglobulin (rabbit)"/>
</dbReference>
<dbReference type="DrugBank" id="DB00063">
<property type="generic name" value="Eptifibatide"/>
</dbReference>
<dbReference type="DrugBank" id="DB13949">
<property type="generic name" value="Ferric cation"/>
</dbReference>
<dbReference type="DrugBank" id="DB15598">
<property type="generic name" value="Ferric maltol"/>
</dbReference>
<dbReference type="DrugBank" id="DB06472">
<property type="generic name" value="Fradafiban"/>
</dbReference>
<dbReference type="DrugBank" id="DB04863">
<property type="generic name" value="Lefradafiban"/>
</dbReference>
<dbReference type="DrugBank" id="DB00451">
<property type="generic name" value="Levothyroxine"/>
</dbReference>
<dbReference type="DrugBank" id="DB05787">
<property type="generic name" value="LM-609"/>
</dbReference>
<dbReference type="DrugBank" id="DB02709">
<property type="generic name" value="Resveratrol"/>
</dbReference>
<dbReference type="DrugBank" id="DB14520">
<property type="generic name" value="Tetraferric tricitrate decahydrate"/>
</dbReference>
<dbReference type="DrugBank" id="DB00775">
<property type="generic name" value="Tirofiban"/>
</dbReference>
<dbReference type="DrugCentral" id="P05106"/>
<dbReference type="GuidetoPHARMACOLOGY" id="2457"/>
<dbReference type="GlyConnect" id="1416">
<property type="glycosylation" value="5 N-Linked glycans (2 sites)"/>
</dbReference>
<dbReference type="GlyGen" id="P05106">
<property type="glycosylation" value="6 sites, 2 N-linked glycans (1 site)"/>
</dbReference>
<dbReference type="iPTMnet" id="P05106"/>
<dbReference type="PhosphoSitePlus" id="P05106"/>
<dbReference type="BioMuta" id="ITGB3"/>
<dbReference type="DMDM" id="125987835"/>
<dbReference type="EPD" id="P05106"/>
<dbReference type="jPOST" id="P05106"/>
<dbReference type="MassIVE" id="P05106"/>
<dbReference type="MaxQB" id="P05106"/>
<dbReference type="PaxDb" id="P05106"/>
<dbReference type="PeptideAtlas" id="P05106"/>
<dbReference type="PRIDE" id="P05106"/>
<dbReference type="ProteomicsDB" id="51790">
<molecule id="P05106-1"/>
</dbReference>
<dbReference type="ProteomicsDB" id="51791">
<molecule id="P05106-2"/>
</dbReference>
<dbReference type="ProteomicsDB" id="51792">
<molecule id="P05106-3"/>
</dbReference>
<dbReference type="ABCD" id="P05106">
<property type="antibodies" value="28 sequenced antibodies"/>
</dbReference>
<dbReference type="Antibodypedia" id="55106">
<property type="antibodies" value="2277 antibodies"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000559488">
<molecule id="P05106-1"/>
<property type="protein sequence ID" value="ENSP00000452786"/>
<property type="gene ID" value="ENSG00000259207"/>
</dbReference>
<dbReference type="GeneID" id="3690"/>
<dbReference type="KEGG" id="hsa:3690"/>
<dbReference type="UCSC" id="uc002ilj.4">
<molecule id="P05106-1"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="3690"/>
<dbReference type="DisGeNET" id="3690"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000259207.7"/>
<dbReference type="GeneCards" id="ITGB3"/>
<dbReference type="HGNC" id="HGNC:6156">
<property type="gene designation" value="ITGB3"/>
</dbReference>
<dbReference type="HPA" id="ENSG00000259207">
<property type="expression patterns" value="Tissue enhanced (thyroid)"/>
</dbReference>
<dbReference type="MalaCards" id="ITGB3"/>
<dbReference type="MIM" id="173470">
<property type="type" value="gene+phenotype"/>
</dbReference>
<dbReference type="MIM" id="187800">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="273800">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P05106"/>
<dbReference type="OpenTargets" id="ENSG00000259207"/>
<dbReference type="Orphanet" id="140957">
<property type="disease" value="Autosomal dominant macrothrombocytopenia"/>
</dbReference>
<dbReference type="Orphanet" id="853">
<property type="disease" value="Fetal and neonatal alloimmune thrombocytopenia"/>
</dbReference>
<dbReference type="Orphanet" id="849">
<property type="disease" value="Glanzmann thrombasthenia"/>
</dbReference>
<dbReference type="PharmGKB" id="PA205"/>
<dbReference type="eggNOG" id="KOG1226">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00980000198528"/>
<dbReference type="HOGENOM" id="CLU_011772_0_1_1"/>
<dbReference type="InParanoid" id="P05106"/>
<dbReference type="KO" id="K06493"/>
<dbReference type="OMA" id="KNPCYSI"/>
<dbReference type="OrthoDB" id="473040at2759"/>
<dbReference type="PhylomeDB" id="P05106"/>
<dbReference type="TreeFam" id="TF105392"/>
<dbReference type="PathwayCommons" id="P05106"/>
<dbReference type="Reactome" id="R-HSA-114608">
<property type="pathway name" value="Platelet degranulation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1566948">
<property type="pathway name" value="Elastic fibre formation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-210990">
<property type="pathway name" value="PECAM1 interactions"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2129379">
<property type="pathway name" value="Molecules associated with elastic fibres"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-216083">
<property type="pathway name" value="Integrin cell surface interactions"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-3000170">
<property type="pathway name" value="Syndecan interactions"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-3000178">
<property type="pathway name" value="ECM proteoglycans"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-354192">
<property type="pathway name" value="Integrin signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-354194">
<property type="pathway name" value="GRB2:SOS provides linkage to MAPK signaling for Integrins"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-372708">
<property type="pathway name" value="p130Cas linkage to MAPK signaling for integrins"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-4420097">
<property type="pathway name" value="VEGFA-VEGFR2 Pathway"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-445144">
<property type="pathway name" value="Signal transduction by L1"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5674135">
<property type="pathway name" value="MAP2K and MAPK activation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6802946">
<property type="pathway name" value="Signaling by moderate kinase activity BRAF mutants"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6802948">
<property type="pathway name" value="Signaling by high-kinase activity BRAF mutants"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6802952">
<property type="pathway name" value="Signaling by BRAF and RAF fusions"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6802955">
<property type="pathway name" value="Paradoxical activation of RAF signaling by kinase inactive BRAF"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-9649948">
<property type="pathway name" value="Signaling downstream of RAS mutants"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-9656223">
<property type="pathway name" value="Signaling by RAF1 mutants"/>
</dbReference>
<dbReference type="SignaLink" id="P05106"/>
<dbReference type="SIGNOR" id="P05106"/>
<dbReference type="BioGRID-ORCS" id="3690">
<property type="hits" value="21 hits in 882 CRISPR screens"/>
</dbReference>
<dbReference type="ChiTaRS" id="ITGB3">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="P05106"/>
<dbReference type="GeneWiki" id="CD61"/>
<dbReference type="GenomeRNAi" id="3690"/>
<dbReference type="Pharos" id="P05106">
<property type="development level" value="Tclin"/>
</dbReference>
<dbReference type="PRO" id="PR:P05106"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 17"/>
</dbReference>
<dbReference type="RNAct" id="P05106">
<property type="molecule type" value="protein"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000259207">
<property type="expression patterns" value="Expressed in left coronary artery and 175 other tissues"/>
</dbReference>
<dbReference type="ExpressionAtlas" id="P05106">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="P05106">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0035868">
<property type="term" value="C:alphav-beta3 integrin-HMGB1 complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0035867">
<property type="term" value="C:alphav-beta3 integrin-IGF-1-IGF1R complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0035866">
<property type="term" value="C:alphav-beta3 integrin-PKCalpha complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0071062">
<property type="term" value="C:alphav-beta3 integrin-vitronectin complex"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0009986">
<property type="term" value="C:cell surface"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005911">
<property type="term" value="C:cell-cell junction"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0070062">
<property type="term" value="C:extracellular exosome"/>
<property type="evidence" value="ECO:0007005"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0031527">
<property type="term" value="C:filopodium membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005925">
<property type="term" value="C:focal adhesion"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005887">
<property type="term" value="C:integral component of plasma membrane"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0034683">
<property type="term" value="C:integrin alphav-beta3 complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008305">
<property type="term" value="C:integrin complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0031258">
<property type="term" value="C:lamellipodium membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042470">
<property type="term" value="C:melanosome"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0031528">
<property type="term" value="C:microvillus membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005654">
<property type="term" value="C:nucleoplasm"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HPA"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0031092">
<property type="term" value="C:platelet alpha granule membrane"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0045211">
<property type="term" value="C:postsynaptic membrane"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0032991">
<property type="term" value="C:protein-containing complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0043235">
<property type="term" value="C:receptor complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0032587">
<property type="term" value="C:ruffle membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045202">
<property type="term" value="C:synapse"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0050839">
<property type="term" value="F:cell adhesion molecule binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0015026">
<property type="term" value="F:coreceptor activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0019899">
<property type="term" value="F:enzyme binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0050840">
<property type="term" value="F:extracellular matrix binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001968">
<property type="term" value="F:fibronectin binding"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042802">
<property type="term" value="F:identical protein binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="IntAct"/>
</dbReference>
<dbReference type="GO" id="GO:0005178">
<property type="term" value="F:integrin binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005161">
<property type="term" value="F:platelet-derived growth factor receptor binding"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0002020">
<property type="term" value="F:protease binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0003756">
<property type="term" value="F:protein disulfide isomerase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043184">
<property type="term" value="F:vascular endothelial growth factor receptor 2 binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0001618">
<property type="term" value="F:virus receptor activity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0032147">
<property type="term" value="P:activation of protein kinase activity"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0060055">
<property type="term" value="P:angiogenesis involved in wound healing"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0038027">
<property type="term" value="P:apolipoprotein A-I-mediated signaling pathway"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043277">
<property type="term" value="P:apoptotic cell clearance"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0007596">
<property type="term" value="P:blood coagulation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0007155">
<property type="term" value="P:cell adhesion"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0033627">
<property type="term" value="P:cell adhesion mediated by integrin"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0016477">
<property type="term" value="P:cell migration"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0007160">
<property type="term" value="P:cell-matrix adhesion"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0031589">
<property type="term" value="P:cell-substrate adhesion"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0030198">
<property type="term" value="P:extracellular matrix organization"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0034113">
<property type="term" value="P:heterotypic cell-cell adhesion"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0007229">
<property type="term" value="P:integrin-mediated signaling pathway"/>
<property type="evidence" value="ECO:0007005"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0050900">
<property type="term" value="P:leukocyte migration"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0048333">
<property type="term" value="P:mesodermal cell differentiation"/>
<property type="evidence" value="ECO:0000270"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0050919">
<property type="term" value="P:negative chemotaxis"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010888">
<property type="term" value="P:negative regulation of lipid storage"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0032369">
<property type="term" value="P:negative regulation of lipid transport"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0050748">
<property type="term" value="P:negative regulation of lipoprotein metabolic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045715">
<property type="term" value="P:negative regulation of low-density lipoprotein particle receptor biosynthetic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0010745">
<property type="term" value="P:negative regulation of macrophage derived foam cell differentiation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0030168">
<property type="term" value="P:platelet activation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070527">
<property type="term" value="P:platelet aggregation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0002576">
<property type="term" value="P:platelet degranulation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0010595">
<property type="term" value="P:positive regulation of endothelial cell migration"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0001938">
<property type="term" value="P:positive regulation of endothelial cell proliferation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0050731">
<property type="term" value="P:positive regulation of peptidyl-tyrosine phosphorylation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0001934">
<property type="term" value="P:positive regulation of protein phosphorylation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0030949">
<property type="term" value="P:positive regulation of vascular endothelial growth factor receptor signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045124">
<property type="term" value="P:regulation of bone resorption"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0032880">
<property type="term" value="P:regulation of protein localization"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0051611">
<property type="term" value="P:regulation of serotonin uptake"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0014909">
<property type="term" value="P:smooth muscle cell migration"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0034446">
<property type="term" value="P:substrate adhesion-dependent cell spreading"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0035295">
<property type="term" value="P:tube development"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0048010">
<property type="term" value="P:vascular endothelial growth factor receptor signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0046718">
<property type="term" value="P:viral entry into host cell"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042060">
<property type="term" value="P:wound healing"/>
<property type="evidence" value="ECO:0000305"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="DisProt" id="DP01842"/>
<dbReference type="Gene3D" id="3.40.50.410">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="InterPro" id="IPR013111">
<property type="entry name" value="EGF_extracell"/>
</dbReference>
<dbReference type="InterPro" id="IPR040622">
<property type="entry name" value="I-EGF_1"/>
</dbReference>
<dbReference type="InterPro" id="IPR027068">
<property type="entry name" value="Integrin_beta-3"/>
</dbReference>
<dbReference type="InterPro" id="IPR033760">
<property type="entry name" value="Integrin_beta_N"/>
</dbReference>
<dbReference type="InterPro" id="IPR015812">
<property type="entry name" value="Integrin_bsu"/>
</dbReference>
<dbReference type="InterPro" id="IPR014836">
<property type="entry name" value="Integrin_bsu_cyt_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR012896">
<property type="entry name" value="Integrin_bsu_tail"/>
</dbReference>
<dbReference type="InterPro" id="IPR036349">
<property type="entry name" value="Integrin_bsu_tail_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR002369">
<property type="entry name" value="Integrin_bsu_VWA"/>
</dbReference>
<dbReference type="InterPro" id="IPR032695">
<property type="entry name" value="Integrin_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR016201">
<property type="entry name" value="PSI"/>
</dbReference>
<dbReference type="InterPro" id="IPR036465">
<property type="entry name" value="vWFA_dom_sf"/>
</dbReference>
<dbReference type="PANTHER" id="PTHR10082">
<property type="entry name" value="PTHR10082"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PANTHER" id="PTHR10082:SF25">
<property type="entry name" value="PTHR10082:SF25"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF07974">
<property type="entry name" value="EGF_2"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF18372">
<property type="entry name" value="I-EGF_1"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF08725">
<property type="entry name" value="Integrin_b_cyt"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF07965">
<property type="entry name" value="Integrin_B_tail"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00362">
<property type="entry name" value="Integrin_beta"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF17205">
<property type="entry name" value="PSI_integrin"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PIRSF" id="PIRSF002512">
<property type="entry name" value="Integrin_B"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PRINTS" id="PR01186">
<property type="entry name" value="INTEGRINB"/>
</dbReference>
<dbReference type="SMART" id="SM00187">
<property type="entry name" value="INB"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM01241">
<property type="entry name" value="Integrin_b_cyt"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM01242">
<property type="entry name" value="Integrin_B_tail"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00423">
<property type="entry name" value="PSI"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF53300">
<property type="entry name" value="SSF53300"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF69179">
<property type="entry name" value="SSF69179"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF69687">
<property type="entry name" value="SSF69687"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00022">
<property type="entry name" value="EGF_1"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="PROSITE" id="PS01186">
<property type="entry name" value="EGF_2"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00243">
<property type="entry name" value="INTEGRIN_BETA"/>
<property type="match status" value="3"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-0130">Cell adhesion</keyword>
<keyword id="KW-0965">Cell junction</keyword>
<keyword id="KW-1003">Cell membrane</keyword>
<keyword id="KW-0966">Cell projection</keyword>
<keyword id="KW-0903">Direct protein sequencing</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-1015">Disulfide bond</keyword>
<keyword id="KW-0325">Glycoprotein</keyword>
<keyword id="KW-1183">Host cell receptor for virus entry</keyword>
<keyword id="KW-0945">Host-virus interaction</keyword>
<keyword id="KW-0401">Integrin</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-0628">Postsynaptic cell membrane</keyword>
<keyword id="KW-0675">Receptor</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0677">Repeat</keyword>
<keyword id="KW-0732">Signal</keyword>
<keyword id="KW-0770">Synapse</keyword>
<keyword id="KW-0812">Transmembrane</keyword>
<keyword id="KW-1133">Transmembrane helix</keyword>
<feature type="signal peptide" evidence="22">
<location>
<begin position="1"/>
<end position="26"/>
</location>
</feature>
<feature type="chain" description="Integrin beta-3" id="PRO_0000016344">
<location>
<begin position="27"/>
<end position="788"/>
</location>
</feature>
<feature type="topological domain" description="Extracellular" evidence="22">
<location>
<begin position="27"/>
<end position="718"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="22">
<location>
<begin position="719"/>
<end position="741"/>
</location>
</feature>
<feature type="topological domain" description="Cytoplasmic" evidence="22">
<location>
<begin position="742"/>
<end position="788"/>
</location>
</feature>
<feature type="domain" description="VWFA">
<location>
<begin position="135"/>
<end position="377"/>
</location>
</feature>
<feature type="repeat" description="I">
<location>
<begin position="463"/>
<end position="511"/>
</location>
</feature>
<feature type="repeat" description="II">
<location>
<begin position="512"/>
<end position="553"/>
</location>
</feature>
<feature type="repeat" description="III">
<location>
<begin position="554"/>
<end position="592"/>
</location>
</feature>
<feature type="repeat" description="IV">
<location>
<begin position="593"/>
<end position="629"/>
</location>
</feature>
<feature type="region of interest" description="Involved in CX3CL1-, NRG1-, FGF1- and IGF1-binding" evidence="56 60 63 66">
<location>
<begin position="203"/>
<end position="210"/>
</location>
</feature>
<feature type="region of interest" description="CX3CL1-binding" evidence="70">
<location>
<begin position="293"/>
<end position="313"/>
</location>
</feature>
<feature type="region of interest" description="Cysteine-rich tandem repeats">
<location>
<begin position="463"/>
<end position="629"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine" evidence="21">
<location>
<position position="767"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine" evidence="20 58">
<location>
<position position="773"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine; by PDPK1 and PKB/AKT1; in vitro" evidence="26">
<location>
<position position="779"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine" evidence="85">
<location>
<position position="785"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="50 51">
<location>
<position position="125"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="22 28">
<location>
<position position="346"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="22 28">
<location>
<position position="397"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine">
<location>
<position position="478"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="22 28">
<location>
<position position="585"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="28 59">
<location>
<position position="680"/>
</location>
</feature>
<feature type="disulfide bond" evidence="61">
<location>
<begin position="31"/>
<end position="461"/>
</location>
</feature>
<feature type="disulfide bond" evidence="61">
<location>
<begin position="39"/>
<end position="49"/>
</location>
</feature>
<feature type="disulfide bond" evidence="61">
<location>
<begin position="42"/>
<end position="75"/>
</location>
</feature>
<feature type="disulfide bond" evidence="61">
<location>
<begin position="52"/>
<end position="64"/>
</location>
</feature>
<feature type="disulfide bond" evidence="61">
<location>
<begin position="203"/>
<end position="210"/>
</location>
</feature>
<feature type="disulfide bond" evidence="61">
<location>
<begin position="258"/>
<end position="299"/>
</location>
</feature>
<feature type="disulfide bond" evidence="61">
<location>
<begin position="400"/>
<end position="412"/>
</location>
</feature>
<feature type="disulfide bond" evidence="61">
<location>
<begin position="432"/>
<end position="681"/>
</location>
</feature>
<feature type="disulfide bond" evidence="61">
<location>
<begin position="459"/>
<end position="463"/>
</location>
</feature>
<feature type="disulfide bond" evidence="99">
<location>
<begin position="474"/>
<end position="486"/>
</location>
</feature>
<feature type="disulfide bond" evidence="99">
<location>
<begin position="483"/>
<end position="521"/>
</location>
</feature>
<feature type="disulfide bond" evidence="99">
<location>
<begin position="488"/>
<end position="497"/>
</location>
</feature>
<feature type="disulfide bond" evidence="99">
<location>
<begin position="499"/>
<end position="512"/>
</location>
</feature>
<feature type="disulfide bond" evidence="99">
<location>
<begin position="527"/>
<end position="532"/>
</location>
</feature>
<feature type="disulfide bond" evidence="99">
<location>
<begin position="529"/>
<end position="562"/>
</location>
</feature>
<feature type="disulfide bond" evidence="99">
<location>
<begin position="534"/>
<end position="547"/>
</location>
</feature>
<feature type="disulfide bond" evidence="61">
<location>
<begin position="549"/>
<end position="554"/>
</location>
</feature>
<feature type="disulfide bond" evidence="99">
<location>
<begin position="568"/>
<end position="573"/>
</location>
</feature>
<feature type="disulfide bond" evidence="99">
<location>
<begin position="570"/>
<end position="601"/>
</location>
</feature>
<feature type="disulfide bond" evidence="99">
<location>
<begin position="575"/>
<end position="584"/>
</location>
</feature>
<feature type="disulfide bond" evidence="99">
<location>
<begin position="586"/>
<end position="593"/>
</location>
</feature>
<feature type="disulfide bond" evidence="99">
<location>
<begin position="607"/>
<end position="612"/>
</location>
</feature>
<feature type="disulfide bond" evidence="99">
<location>
<begin position="609"/>
<end position="657"/>
</location>
</feature>
<feature type="disulfide bond" evidence="99">
<location>
<begin position="614"/>
<end position="624"/>
</location>
</feature>
<feature type="disulfide bond" evidence="99">
<location>
<begin position="627"/>
<end position="630"/>
</location>
</feature>
<feature type="disulfide bond" evidence="99">
<location>
<begin position="634"/>
<end position="643"/>
</location>
</feature>
<feature type="disulfide bond" evidence="99">
<location>
<begin position="640"/>
<end position="713"/>
</location>
</feature>
<feature type="disulfide bond" evidence="61">
<location>
<begin position="661"/>
<end position="689"/>
</location>
</feature>
<feature type="splice variant" description="In isoform Beta-3B." id="VSP_002745" evidence="96">
<original>ANNPLYKEATSTFTNITYRGT</original>
<variation>VRDGAGRFLKSLV</variation>
<location>
<begin position="768"/>
<end position="788"/>
</location>
</feature>
<feature type="splice variant" description="In isoform Beta-3C." id="VSP_002746" evidence="97">
<original>ANNPLYKEATSTFTNITYRGT</original>
<variation>HYAQSLRKWNQPVSIDG</variation>
<location>
<begin position="768"/>
<end position="788"/>
</location>
</feature>
<feature type="sequence variant" description="In alloantigen HPA-1B; dbSNP:rs5918." id="VAR_003993" evidence="24 72 77 93">
<original>L</original>
<variation>P</variation>
<location>
<position position="59"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; severe type 1 phenotype; the mutation prevents normal ITGA2B/ITGB3 complex expression; dbSNP:rs74554539." id="VAR_069920" evidence="62">
<original>C</original>
<variation>Y</variation>
<location>
<position position="64"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs36080296." id="VAR_049633" evidence="93">
<original>L</original>
<variation>R</variation>
<location>
<position position="66"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; dbSNP:rs781062792." id="VAR_030473" evidence="34">
<original>R</original>
<variation>W</variation>
<location>
<position position="119"/>
</location>
</feature>
<feature type="sequence variant" description="In GT." id="VAR_030474" evidence="45">
<original>Y</original>
<variation>C</variation>
<location>
<position position="141"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; dbSNP:rs121918452." id="VAR_010649" evidence="89">
<original>L</original>
<variation>W</variation>
<location>
<position position="143"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; severe type 1 phenotype; the mutation prevented normal ITGA2B/ITGB3 complex expression on the cell surface; dbSNP:rs77963874." id="VAR_069921" evidence="62">
<original>M</original>
<variation>R</variation>
<location>
<position position="144"/>
</location>
</feature>
<feature type="sequence variant" description="In GT." id="VAR_030475" evidence="88">
<original>D</original>
<variation>N</variation>
<location>
<position position="145"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; type B; dbSNP:rs121918445." id="VAR_003998" evidence="68">
<original>D</original>
<variation>Y</variation>
<location>
<position position="145"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; may confer constitutive activity to the alpha-IIb/(mutated)beta-3 receptor; dbSNP:rs767548512." id="VAR_030476" evidence="43">
<original>M</original>
<variation>V</variation>
<location>
<position position="150"/>
</location>
</feature>
<feature type="sequence variant" description="Associated with neonatal thrombocytopenia; alloantigen Duv(a+); does not affect significantly the integrin function; dbSNP:rs74708909." id="VAR_030477" evidence="33">
<original>T</original>
<variation>I</variation>
<location>
<position position="166"/>
</location>
</feature>
<feature type="sequence variant" description="In alloantigen HPA-4B; dbSNP:rs5917." id="VAR_003994" evidence="24 39">
<original>R</original>
<variation>Q</variation>
<location>
<position position="169"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; type II; dbSNP:rs143146734." id="VAR_010651" evidence="91">
<original>S</original>
<variation>L</variation>
<location>
<position position="188"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; variant form; dbSNP:rs79208797." id="VAR_030478" evidence="31 62">
<original>L</original>
<variation>P</variation>
<location>
<position position="222"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; type B; dbSNP:rs121918444." id="VAR_003999" evidence="38 77">
<original>R</original>
<variation>Q</variation>
<location>
<position position="240"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; variant Strasbourg-1; dbSNP:rs121918446." id="VAR_004000" evidence="47">
<original>R</original>
<variation>W</variation>
<location>
<position position="240"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; dbSNP:rs377162158." id="VAR_030479" evidence="88">
<original>R</original>
<variation>Q</variation>
<location>
<position position="242"/>
</location>
</feature>
<feature type="sequence variant" description="In GT." id="VAR_030480" evidence="34">
<original>D</original>
<variation>V</variation>
<location>
<position position="243"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; severe type 1 phenotype; the mutation prevents normal ITGA2B/ITGB3 complex expression on the cell surface; the mutation may interfere with correct folding of the protein; dbSNP:rs79560904." id="VAR_069922" evidence="62">
<original>G</original>
<variation>D</variation>
<location>
<position position="247"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; severe type 1 phenotype; the mutation prevents normal ITGA2B/ITGB3 complex expression on the cell surface; the mutation interupts the interaction of the ITGA2B/ITGB3 complex; dbSNP:rs79775494." id="VAR_069923" evidence="62">
<original>K</original>
<variation>M</variation>
<location>
<position position="279"/>
</location>
</feature>
<feature type="sequence variant" description="In GT." id="VAR_030481" evidence="88">
<original>L</original>
<variation>P</variation>
<location>
<position position="288"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; dbSNP:rs13306476." id="VAR_004001" evidence="44 92">
<original>H</original>
<variation>P</variation>
<location>
<position position="306"/>
</location>
</feature>
<feature type="sequence variant" description="In GT." id="VAR_030482" evidence="45">
<original>M</original>
<variation>L</variation>
<location>
<position position="321"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; not expressed on the surface and absent inside the transfected cells." id="VAR_030483" evidence="44">
<original>I</original>
<variation>N</variation>
<location>
<position position="330"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; dbSNP:rs121918449." id="VAR_004002" evidence="86">
<original>C</original>
<variation>Y</variation>
<location>
<position position="400"/>
</location>
</feature>
<feature type="sequence variant" description="In alloantigen MO(+); in a case of neonatal alloimmune thrombocytopenia; dbSNP:rs121918448." id="VAR_003995" evidence="83">
<original>P</original>
<variation>A</variation>
<location>
<position position="433"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs5921." id="VAR_014178" evidence="24">
<original>V</original>
<variation>I</variation>
<location>
<position position="453"/>
</location>
</feature>
<feature type="sequence variant" description="In alloantigen CA(+)/TU(+); dbSNP:rs13306487." id="VAR_003996" evidence="82">
<original>R</original>
<variation>Q</variation>
<location>
<position position="515"/>
</location>
</feature>
<feature type="sequence variant" description="In GT." id="VAR_030484" evidence="35">
<original>C</original>
<variation>Y</variation>
<location>
<position position="532"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; type I." id="VAR_010671" evidence="23">
<original>C</original>
<variation>R</variation>
<location>
<position position="568"/>
</location>
</feature>
<feature type="sequence variant" description="In GT." id="VAR_004003" evidence="92">
<original>C</original>
<variation>F</variation>
<location>
<position position="586"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; gain-of-function mutation; constitutively binds ligand-induced binding sites antibodies and the fibrinogen-mimetic antibody PAC-1." id="VAR_030485" evidence="29">
<original>C</original>
<variation>R</variation>
<location>
<position position="586"/>
</location>
</feature>
<feature type="sequence variant" description="In GT." id="VAR_004004" evidence="92">
<original>G</original>
<variation>S</variation>
<location>
<position position="598"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; dbSNP:rs747534508." id="VAR_030486" evidence="34">
<original>C</original>
<variation>R</variation>
<location>
<position position="601"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; type II; dbSNP:rs144884023." id="VAR_010672" evidence="92">
<original>G</original>
<variation>S</variation>
<location>
<position position="605"/>
</location>
</feature>
<feature type="sequence variant" description="In alloantigen SR(A); dbSNP:rs151219882." id="VAR_003997" evidence="84">
<original>R</original>
<variation>C</variation>
<location>
<position position="662"/>
</location>
</feature>
<feature type="sequence variant" description="In BDPLT16; the mutant protein is spountaneous partally active; decreased platelet surface expression; spontaneous FAK phosphosphorylation; abnormal cell shape." id="VAR_081732" evidence="79">
<location>
<position position="746"/>
</location>
</feature>
<feature type="sequence variant" description="In BDPLT16; the mutant protein is constitutively active; spontaneous FAK phosphosphorylation; abnormal cell shape; dbSNP:rs398122372." id="VAR_069924" evidence="55 79">
<original>D</original>
<variation>H</variation>
<location>
<position position="749"/>
</location>
</feature>
<feature type="sequence variant" description="In GT; variant Strasbourg-1; dbSNP:rs121918447." id="VAR_004005" evidence="40">
<original>S</original>
<variation>P</variation>
<location>
<position position="778"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; AAA52589 and 3; AAA35927." ref="1 3" evidence="98">
<original>A</original>
<variation>V</variation>
<location>
<position position="12"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 11; AAA67537 and 14; AAB23689." ref="11 14" evidence="98">
<original>K</original>
<variation>P</variation>
<location>
<position position="151"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 11; AAA67537." ref="11" evidence="98">
<original>D</original>
<variation>EY</variation>
<location>
<position position="205"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; AAA52589, 2; AAA60122 and 4; AAB71380." ref="1 2 4" evidence="98">
<original>GALHD</original>
<variation>EPYMT</variation>
<location>
<begin position="649"/>
<end position="653"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 8." ref="8" evidence="98">
<original>G</original>
<variation>H</variation>
<location>
<position position="716"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 11; AAA67537." ref="11" evidence="98">
<original>ALLIW</original>
<variation>PCSSG</variation>
<location>
<begin position="737"/>
<end position="741"/>
</location>
</feature>
<feature type="turn" evidence="18">
<location>
<begin position="30"/>
<end position="34"/>
</location>
</feature>
<feature type="helix" evidence="15">
<location>
<begin position="35"/>
<end position="37"/>
</location>
</feature>
<feature type="helix" evidence="18">
<location>
<begin position="39"/>
<end position="45"/>
</location>
</feature>
<feature type="strand" evidence="12">
<location>
<begin position="50"/>
<end position="52"/>
</location>
</feature>
<feature type="strand" evidence="17">
<location>
<begin position="55"/>
<end position="57"/>
</location>
</feature>
<feature type="strand" evidence="8">
<location>
<begin position="59"/>
<end position="61"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="63"/>
<end position="65"/>
</location>
</feature>
<feature type="helix" evidence="18">
<location>
<begin position="67"/>
<end position="72"/>
</location>
</feature>
<feature type="turn" evidence="18">
<location>
<begin position="77"/>
<end position="79"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="86"/>
<end position="91"/>
</location>
</feature>
<feature type="strand" evidence="12">
<location>
<begin position="99"/>
<end position="101"/>
</location>
</feature>
<feature type="helix" evidence="13">
<location>
<begin position="103"/>
<end position="105"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="109"/>
<end position="111"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="113"/>
<end position="118"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="123"/>
<end position="131"/>
</location>
</feature>
<feature type="strand" evidence="12">
<location>
<begin position="138"/>
<end position="145"/>
</location>
</feature>
<feature type="helix" evidence="12">
<location>
<begin position="148"/>
<end position="150"/>
</location>
</feature>
<feature type="helix" evidence="12">
<location>
<begin position="151"/>
<end position="156"/>
</location>
</feature>
<feature type="turn" evidence="12">
<location>
<begin position="157"/>
<end position="159"/>
</location>
</feature>
<feature type="helix" evidence="12">
<location>
<begin position="160"/>
<end position="168"/>
</location>
</feature>
<feature type="turn" evidence="12">
<location>
<begin position="169"/>
<end position="171"/>
</location>
</feature>
<feature type="strand" evidence="12">
<location>
<begin position="175"/>
<end position="182"/>
</location>
</feature>
<feature type="turn" evidence="12">
<location>
<begin position="188"/>
<end position="190"/>
</location>
</feature>
<feature type="helix" evidence="12">
<location>
<begin position="196"/>
<end position="200"/>
</location>
</feature>
<feature type="turn" evidence="12">
<location>
<begin position="202"/>
<end position="207"/>
</location>
</feature>
<feature type="strand" evidence="12">
<location>
<begin position="215"/>
<end position="224"/>
</location>
</feature>
<feature type="helix" evidence="12">
<location>
<begin position="226"/>
<end position="235"/>
</location>
</feature>
<feature type="strand" evidence="12">
<location>
<begin position="242"/>
<end position="246"/>
</location>
</feature>
<feature type="helix" evidence="12">
<location>
<begin position="248"/>
<end position="257"/>
</location>
</feature>
<feature type="helix" evidence="12">
<location>
<begin position="259"/>
<end position="262"/>
</location>
</feature>
<feature type="strand" evidence="12">
<location>
<begin position="266"/>
<end position="278"/>
</location>
</feature>
<feature type="helix" evidence="12">
<location>
<begin position="285"/>
<end position="289"/>
</location>
</feature>
<feature type="strand" evidence="16">
<location>
<begin position="305"/>
<end position="307"/>
</location>
</feature>
<feature type="turn" evidence="12">
<location>
<begin position="308"/>
<end position="312"/>
</location>
</feature>
<feature type="helix" evidence="12">
<location>
<begin position="318"/>
<end position="327"/>
</location>
</feature>
<feature type="strand" evidence="12">
<location>
<begin position="331"/>
<end position="336"/>
</location>
</feature>
<feature type="helix" evidence="12">
<location>
<begin position="338"/>
<end position="340"/>
</location>
</feature>
<feature type="helix" evidence="12">
<location>
<begin position="341"/>
<end position="349"/>
</location>
</feature>
<feature type="strand" evidence="12">
<location>
<begin position="355"/>
<end position="358"/>
</location>
</feature>
<feature type="turn" evidence="13">
<location>
<begin position="361"/>
<end position="363"/>
</location>
</feature>
<feature type="helix" evidence="12">
<location>
<begin position="366"/>
<end position="377"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="381"/>
<end position="387"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="392"/>
<end position="399"/>
</location>
</feature>
<feature type="turn" evidence="12">
<location>
<begin position="401"/>
<end position="403"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="405"/>
<end position="407"/>
</location>
</feature>
<feature type="strand" evidence="17">
<location>
<begin position="410"/>
<end position="414"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="420"/>
<end position="429"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="438"/>
<end position="444"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="451"/>
<end position="457"/>
</location>
</feature>
<feature type="helix" evidence="18">
<location>
<begin position="462"/>
<end position="466"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="468"/>
<end position="470"/>
</location>
</feature>
<feature type="turn" evidence="13">
<location>
<begin position="472"/>
<end position="474"/>
</location>
</feature>
<feature type="turn" evidence="18">
<location>
<begin position="475"/>
<end position="477"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="479"/>
<end position="482"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="485"/>
<end position="487"/>
</location>
</feature>
<feature type="strand" evidence="10">
<location>
<begin position="489"/>
<end position="491"/>
</location>
</feature>
<feature type="turn" evidence="17">
<location>
<begin position="494"/>
<end position="498"/>
</location>
</feature>
<feature type="strand" evidence="10">
<location>
<begin position="500"/>
<end position="504"/>
</location>
</feature>
<feature type="strand" evidence="19">
<location>
<begin position="505"/>
<end position="508"/>
</location>
</feature>
<feature type="helix" evidence="17">
<location>
<begin position="509"/>
<end position="511"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="512"/>
<end position="518"/>
</location>
</feature>
<feature type="helix" evidence="18">
<location>
<begin position="520"/>
<end position="523"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="524"/>
<end position="528"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="531"/>
<end position="534"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="538"/>
<end position="540"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="542"/>
<end position="544"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="549"/>
<end position="552"/>
</location>
</feature>
<feature type="strand" evidence="9">
<location>
<begin position="556"/>
<end position="561"/>
</location>
</feature>
<feature type="helix" evidence="18">
<location>
<begin position="562"/>
<end position="564"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="565"/>
<end position="569"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="572"/>
<end position="575"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="579"/>
<end position="581"/>
</location>
</feature>
<feature type="helix" evidence="18">
<location>
<begin position="591"/>
<end position="593"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="598"/>
<end position="600"/>
</location>
</feature>
<feature type="helix" evidence="18">
<location>
<begin position="601"/>
<end position="603"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="604"/>
<end position="608"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="611"/>
<end position="614"/>
</location>
</feature>
<feature type="turn" evidence="10">
<location>
<begin position="616"/>
<end position="618"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="620"/>
<end position="624"/>
</location>
</feature>
<feature type="strand" evidence="14">
<location>
<begin position="628"/>
<end position="630"/>
</location>
</feature>
<feature type="helix" evidence="18">
<location>
<begin position="633"/>
<end position="645"/>
</location>
</feature>
<feature type="helix" evidence="18">
<location>
<begin position="650"/>
<end position="653"/>
</location>
</feature>
<feature type="helix" evidence="18">
<location>
<begin position="657"/>
<end position="660"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="663"/>
<end position="670"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="676"/>
<end position="684"/>
</location>
</feature>
<feature type="turn" evidence="2">
<location>
<begin position="686"/>
<end position="688"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="690"/>
<end position="697"/>
</location>
</feature>
<feature type="strand" evidence="9">
<location>
<begin position="698"/>
<end position="700"/>
</location>
</feature>
<feature type="strand" evidence="18">
<location>
<begin position="703"/>
<end position="710"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="715"/>
<end position="717"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="743"/>
<end position="759"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="761"/>
<end position="765"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="767"/>
<end position="770"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="771"/>
<end position="774"/>
</location>
</feature>
<feature type="helix" evidence="7">
<location>
<begin position="776"/>
<end position="779"/>
</location>
</feature>
<feature type="turn" evidence="4">
<location>
<begin position="782"/>
<end position="786"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1KUP"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1M1X"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1MK7"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1S4X"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1U8C"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2KNC"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2LJD"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2VDO"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3FCS"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3IJE"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3NID"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3T3P"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3ZE2"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4G1E"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4MMX"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5HDB"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000244">
<source>
<dbReference type="PDB" id="6BXB"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000244">
<source>
<dbReference type="PDB" id="6BXJ"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000244">
<source>
<dbReference type="PDB" id="6MK0"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="18088087"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="O54890"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000255"/>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10233432"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10391209"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10397733"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10896934"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11160695"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11546839"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11588040"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11807098"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11897046"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11940607"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12036875"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12083483"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12353082"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12695522"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12807887"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1371279"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1430225"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1438206"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15156152"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15466936"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15583747"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15634267"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15748237"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15834425"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1602006"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16051604"/>
</source>
</evidence>
<evidence key="49" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16216233"/>
</source>
</evidence>
<evidence key="50" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16263699"/>
</source>
</evidence>
<evidence key="51" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16335952"/>
</source>
</evidence>
<evidence key="52" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16982628"/>
</source>
</evidence>
<evidence key="53" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17583734"/>
</source>
</evidence>
<evidence key="54" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18045938"/>
</source>
</evidence>
<evidence key="55" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18065693"/>
</source>
</evidence>
<evidence key="56" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18441324"/>
</source>
</evidence>
<evidence key="57" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18635536"/>
</source>
</evidence>
<evidence key="58" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19141530"/>
</source>
</evidence>
<evidence key="59" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19159218"/>
</source>
</evidence>
<evidence key="60" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19578119"/>
</source>
</evidence>
<evidence key="61" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2001252"/>
</source>
</evidence>
<evidence key="62" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20020534"/>
</source>
</evidence>
<evidence key="63" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20682778"/>
</source>
</evidence>
<evidence key="64" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20702409"/>
</source>
</evidence>
<evidence key="65" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22492581"/>
</source>
</evidence>
<evidence key="66" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23125415"/>
</source>
</evidence>
<evidence key="67" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23658209"/>
</source>
</evidence>
<evidence key="68" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2392682"/>
</source>
</evidence>
<evidence key="69" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="24478423"/>
</source>
</evidence>
<evidence key="70" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="24789099"/>
</source>
</evidence>
<evidence key="71" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="25398877"/>
</source>
</evidence>
<evidence key="72" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2565345"/>
</source>
</evidence>
<evidence key="73" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="27993971"/>
</source>
</evidence>
<evidence key="74" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="28302677"/>
</source>
</evidence>
<evidence key="75" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="28873464"/>
</source>
</evidence>
<evidence key="76" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="29030430"/>
</source>
</evidence>
<evidence key="77" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="29084015"/>
</source>
</evidence>
<evidence key="78" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="29301984"/>
</source>
</evidence>
<evidence key="79" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="29380037"/>
</source>
</evidence>
<evidence key="80" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="31331973"/>
</source>
</evidence>
<evidence key="81" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7519807"/>
</source>
</evidence>
<evidence key="82" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7694683"/>
</source>
</evidence>
<evidence key="83" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8093349"/>
</source>
</evidence>
<evidence key="84" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8132570"/>
</source>
</evidence>
<evidence key="85" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8631894"/>
</source>
</evidence>
<evidence key="86" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8781422"/>
</source>
</evidence>
<evidence key="87" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9195946"/>
</source>
</evidence>
<evidence key="88" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9215749"/>
</source>
</evidence>
<evidence key="89" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9376589"/>
</source>
</evidence>
<evidence key="90" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9618541"/>
</source>
</evidence>
<evidence key="91" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9684783"/>
</source>
</evidence>
<evidence key="92" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9790984"/>
</source>
</evidence>
<evidence key="93" type="ECO:0000269">
<source ref="13"/>
</evidence>
<evidence key="94" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="16322781"/>
</source>
</evidence>
<evidence key="95" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="17635696"/>
</source>
</evidence>
<evidence key="96" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="2787511"/>
</source>
</evidence>
<evidence key="97" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="9195946"/>
</source>
</evidence>
<evidence key="98" type="ECO:0000305"/>
<evidence key="99" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="2001252"/>
</source>
</evidence>
<evidence key="100" type="ECO:0000312">
<source>
<dbReference type="HGNC" id="HGNC:6156"/>
</source>
</evidence>
<sequence length="788" mass="87058" checksum="F246623608E05F9E" modified="2007-02-06" version="2" precursor="true">MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGT</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
</copyright>
</uniprot>

